94 results on '"Xavier Iriart"'
Search Results
2. Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: A national post-authorization pharmacovigilance study
- Author
-
Naïm Ouldali, Haleh Bagheri, Francesco Salvo, Denise Antona, Antoine Pariente, Claire Leblanc, Martine Tebacher, Joëlle Micallef, Corinne Levy, Robert Cohen, Etienne Javouhey, Brigitte Bader-Meunier, Caroline Ovaert, Sylvain Renolleau, Veronique Hentgen, Isabelle Kone-Paut, Nina Deschamps, Loïc De Pontual, Xavier Iriart, Christelle Gras-Le Guen, François Angoulvant, Alexandre Belot, Aurelie Donzeau, Layal El Aridi, Sophie Lety, Bertrand Leboucher, Agnes Baur, Lucas Jeusset, Maelle Selegny, Cristian Fedorczuk, Marion Lajus, Philippe Bensaid, Yacine Laoudi, Charlotte Pons, Anne-Cécile Robert, Camille Beaucourt, Muriel Richard, Etienne Goisque, Olivier Brissaud, Pierre Segretin, Julie Molimard, Marie-Clothilde Orecel, Gregoire Benoit, Lucille Bongiovanni, Margaux Guerder, Robin Pouyau, Jean-Marie De Guillebon De Resnes, Ellia Mezgueldi, Fleur Cour-Andlauer, Come Horvat, Pierre Poinsot, Cecile Frachette, Antoine Ouziel, Yves Gillet, Catherine Barrey, Jacques Brouard, Florence Villedieu, Vathanaksambath Ro, Narcisse Elanga, Vincent Gajdos, Romain Basmaci, Hadile Mutar, Sébastien Rouget, Elodie Nattes, Isabelle Hau, Sandra Biscardi, Houmam El Jurdi, Camille Jung, Denis Semama, Frederic Huet, Anne-Marie Zoccarato, Mayssa Sarakbi, Guillaume Mortamet, Cécile Bost-Bru, Joachim Bassil, Caroline Vinit, Véronique Hentgen, Pascal Leroux, Valérie Bertrand, Caroline Parrod, Irina Craiu, Philippe Durand, Pierre Tissiere, Caroline Claude, Guillaume Morelle, Tamazoust Guiddir, Charlotte Borocco, Frédérique Delion, Camille Guillot, Stéphane Leteurtre, François Dubos, Mylene Jouancastay, Alain Martinot, Valentine Voeusler, Jeanne Languepin, Nathalie Garrec, Arnaud Chalvon Demersay, Aurélie Morand, Emmanuelle Bosdure, Noémie Vanel, Fabrice Ughetto, Fabrice Michel, Marie Caujolle, Renaud Blonde, Jacqueline Nguyen, Olivier Vignaud, Caroline Masserot-Lureau, François Gouraud, Carine Araujo, Tara Ingrao, Sanaa Naji, Mohammed Sehaba, Christine Roche, Aurelia Carbasse, Christophe Milesi, Mustapha Mazeghrane, Sandrine Haupt, Cyril Schweitzer, Benedicte Romefort, Elise Launay, Christèle Gras-Le Guen, Ahmed Ali, Nathalie Blot, Antoine Tran, Anne Rancurel, Mickael Afanetti, Sophie Odorico, Deborah Talmud, Anais Chosidow, Anne-Sophie Romain, Emmanuel Grimprel, Marie Pouletty, Jean Gaschignard, Olivier Corseri, Albert Faye, Isabelle Melki, Camille Ducrocq, Cherine Benzoïd, Johanna Lokmer, Stéphane Dauger, Maryline Chomton, Anna Deho, Fleur Lebourgeois, Fabrice Lesage, Florence Moulin, Laurent Dupic, Yael Pinhas, Agathe Debray, Martin Chalumeau, Véronique Abadie, Pierre Frange, Jeremie F Cohen, Slimane Allali, William Curtis, Zahra Belhadjer, Johanne Auriau, Mathilde Méot, Lucile Houyel, Damien Bonnet, Christophe Delacourt, Brigitte Bader Meunier, Pierre Quartier, Youssef Shaim, Laurence Baril, Samuel Crommelynck, Baptiste Jacquot, Philippe Blanc, Natacha Maledon, Blandine Robert, Camille Loeile, Clémence Cazau, Gauthier Loron, Simona Gaga, Cécile Vittot, Loubna El Nabhani, François Buisson, Muriel Prudent, Hugues Flodrops, Fadhila Mokraoui, Simon Escoda, Laurent Bonnemains, Sarah-Louisa Mahi, Clara Mertes, Joelle Terzic, Julie Helms, Charlotte Idier, Soraya Chenichene, Nicoleta Magdolena Ursulescu, Gladys Beaujour, Abdelhak Hakim, Alice Miquel, Agnès Rey, Arnaud Wiedermann, Anne Charbonneau, Agnès Veauvy-Juven, Alexandrine Ferry, Alexis Mandelcwajg, Alix Rousseau, Amandine Prenant, Anne-Laure Bourneuf, Anne Filleron, Audrey Robine, Arthur Félix, Aude Parizel, Aurélie Labarre, Aymeric Cantais, Barbara Ros, Basile Coulon, Blandine Biot, Bérengère Dalichoux, Benjamin Fournier, Benoit Cagnard, Blandine Vanel, David Brossier, Bruno Ménager, Bruno Ozanne, Carole Marie-Jeanne, Camille Bergerot, Camille Chavy, Camille Guidon, Candice Fabre, Caroline Galeotti, Catherine Baker, Claire Ballot-Schmit, Céline Belleau, Céline Charasse, Caroline Favel, Chadia Toumi, Charlène Ferrandiz, Charlotte Couturier, Charlotte Pouchoux, Maryline Chomton-Cailliez, Charlotte Kevorkian-Verguet, Clément Brunet, Céline Manteau, Clémence Mougey, Coline Santy, Coralie Fitament, Charlotte Petriat, Charlotte Rebelle, Cyril Charron, Maxime Dartus, David Toulorge, Cécile Guillou-Debuisson, Dorann Bartebin, Valérie Klein, E Broustal, E Desselas, Elodie Marteau, Emmanuelle Bouvrot, Elise Delacroix, Edeline Coinde, Loubna Elnabhani, Elsa Amouyal, Emilie Chaillou, Emeline Gabilly-Bernard, Emilie Ruiz, Emilie Thibault, Emilie Robin, Etienne Darrieux, Eva Blondel, Floriane Socchi, François Cazassus, Fanny Bajolle, Fatma Lacin, Fouad Madhi, Franck Zekre, François Guerin, Gerald Boussicault, Henri Ginies, Gnansounou Magloire, Guilhem Arnold, Ines Coulognon, Iona Sicard-Cras, Jean-Emmanuel Kahn, Jeanne Bordet, Jeanne-Lise Fausser, Jean-François Baleine, Josephine Brice, Julie Gendras, Kaan Pekin, Karine Norbert, Clément Karsenty, Léa Savary, Laurence Martinat, Léa Lesniewski, Lorelei Charbonnier, Louise Alexandre, Lucas Percheron, Marie Vincenti, Manon Lanzini, Margot Grisval, Marianne Mercy, Marie-Emilie Lampin, Marie Desgranges, Marie Duperril, Marie-Clothilde Orcel, Marion Audier, Marion Favier, Mathieu Carpentier, Mathilde Balcean, Mathilde Bonnet, Maurine Jouret, Marie Delattre, Michael Levy, Michael Valensi, Mickael Shum, Morgane Dumortier, Morgane Gelin, Morgane Nemmouchi, Morgane Williaume, M Sebaha, Nicoleta Genetay-Stanescu, Nathan Giroux, Nicolas Crassard, Neil Derridj, Noemie Lachaume, Oscar Werner, Olivier Guilluy, Olivier Richer, Olivier Tirel, Aurianne Pauvert, Paul Casha, Noémie Perez, Pauline Gras, Pierre-Louis Leger, Marion Pinchou, Pierre Mornand, Prisca Largo, Ramona-Christina Ibanez, Charlotte Roulland, Salam Hadah Albarazi, Said Bichali, Sarah Faton, Amandine Schott, Sébastien Walser, Severine Guillaume, Solene Vincent, Sophie Galene-Gromez, Stanislas Kozisek, Thierry Maugard, Thierry Blanc, Thierry Navarro, Thomas Lauvray, Tamas Kovacs, Valérie Launay, Véronique Despert, Victoria Lhostis, Virginie Gall, Xavier Micaelli, Yasmine Benadjaoud, Zied Matoussi, Hélène Géniaux, Anthony Facile, Tessa Pietri, Pascale Palassin, Sylvine Pinel, Laurent Chouchana, Delphine Callot, Charlène Boulay, Hôpital Robert Debré, CHU Sainte Justine [Montréal], Association Clinique et Thérapeutique Infantile du Val de Marne (ACTIV), Epidémiologie Clinique et Evaluation Economique Appliquées aux Populations Vulnérables (ECEVE (U1123 / UMR_S_1123)), Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Bordeaux [Bordeaux], Santé publique France - French National Public Health Agency [Saint-Maurice, France], Les Hôptaux universitaires de Strasbourg (HUS), CHU Strasbourg, CHU Marseille, Institut de Neurosciences des Systèmes (INS), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHI Créteil, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Femme Mère Enfant [CHU - HCL] (HFME), Hospices Civils de Lyon (HCL), Physiopathologie de l'immunodépression associée aux réponses inflammatoires systémiques / Pathophysiology of Injury-induced Immunosuppression (PI3), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Référence pour les Maladies Rhumatologiques Auto-Immunes et Systémiques [CHU Necker] (RAISE), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital de la Timone [CHU - APHM] (TIMONE), Marseille medical genetics - Centre de génétique médicale de Marseille (MMG), Evaluation thérapeutique et pharmacologie périnatale et pédiatrique (EA_7323), Université Paris Descartes - Paris 5 (UPD5), Centre Hospitalier de Versailles André Mignot (CHV), Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses [CH Versailles] (CeRéMAIA - Hôpital André Mignot), Hôpital Bicêtre, Université Paris-Saclay, CH de Saint-Malo [Broussais], Hôpital Jean Verdier [AP-HP], Institut de rythmologie et modélisation cardiaque [Pessac] (IHU Liryc), Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] (CRCTB), Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de référence des rhumatismes inflammatoires et maladies auto-immunes systémiques rares de l’enfant / National Referee Centre for Rheumatic and AutoImmune and Systemic Diseases in Children [Lyon] (RAISE), European Society for Paediatric Infectious Diseases, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPC), CHU Toulouse [Toulouse], Physiopathologie de l'immunodépression associée aux réponses inflammatoires systémiques - EA 7426 (PI3), Centre de Référence pour les Maladies Rhumatologiques Auto-Immunes et Systémiques [Paris] (Institut IMAGINE/RAISE), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut Imagine [Paris Necker] (2I), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC), HESAM Université (HESAM)-HESAM Université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPC), Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Health data- and model- driven Knowledge Acquisition (HeKA), Inria de Paris, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), and Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité)-École Pratique des Hautes Études (EPHE)
- Subjects
Oncology ,[SDV]Life Sciences [q-bio] ,Health Policy ,Multisystem inflammatory syndrome in children ,Internal Medicine ,COVID-19 mRNA vaccine ,BNT162b2 ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,SARS-COV-2 ,Hyper-inflammatory syndrome ,Child - Abstract
International audience; BACKGROUND: Multisystem inflammatory syndrome in children (MIS-C) is the most severe clinical entity associated with pediatric SARS-CoV-2 infection with a putative role of the spike protein into the immune system activation. Whether COVID-19 mRNA vaccine can induce this complication in children is unknown. We aimed to assess the risk of hyper-inflammatory syndrome following COVID-19 mRNA vaccine in children. METHODS: We conducted a post-authorization national population-based surveillance using the French enhanced pharmacovigilance surveillance system for COVID-19 vaccines. All cases of suspected hyper-inflammatory syndrome following COVID-19 mRNA vaccine in 12-17-year-old children between June 15(th), 2021 and January 1(st), 2022, were reported. Cases were reviewed according to WHO criteria for MIS-C. The reporting rate of this syndrome was compared to the MIS-C rate per 1,000,000 12-17-year-old children infected by SARS-CoV-2. FINDINGS: Up to January 2022, 8,113,058 COVID-19 mRNA vaccine doses were administered to 4,079,234 12-17-year-old children. Among them, 12 presented a hyper-inflammatory syndrome with multisystemic involvement. Main clinical features included male predominance (10/12, 83%), cardiac involvement (10/12, 83%), digestive symptoms (10/12, 83%), coagulopathy (7/12, 58%), cytolytic hepatitis (6/12, 50%), and shock (5/12, 42%). 4/12 (33%) required intensive care unit transfer, and 3/12 (25%) hemodynamic support. All cases recovered. In eight cases, no evidence of previous SARS-CoV-2 infection was found. The reporting rate was 1.5 (95%CI [0.8; 2.6]) per 1,000,000 doses injected, i.e. 2.9 (95%CI [1.5; 5.1]) per 1,000,000 12-17-year-old vaccinated children. As a comparison, 113 MIS-C (95%CI [95; 135]) occurred per 1,000,000 12-17-year-old children infected by SARS-CoV-2. INTERPRETATION: Very few cases of hyper-inflammatory syndrome with multi-organ involvement occurred following COVID-19 mRNA vaccine in 12-17-year-old children. The low reporting rate of this syndrome, compared to the rate of post-SARS-CoV-2 MIS-C in the same age-group, largely supports the vaccination in a context of an important circulation of SARS-CoV-2. FUNDING: ESPID Fellowship Award; Grandir-Fonds de Solidarité Pour L'enfance.
- Published
- 2022
3. Ventricular tachycardia in a patient with repaired d-transposition of the great arteries
- Author
-
Nadir Tafer, Konstantinos Vlachos, Xavier Iriart, Frederic Sacher, Philipp Krisai, and Hubert Cochet
- Subjects
medicine.medical_specialty ,Heart disease ,medicine.medical_treatment ,Case Report ,Ablation ,Ventricular tachycardia ,Transposition (music) ,Internal medicine ,medicine ,Transposition of the great arteries ,Adult congenital heart disease ,In patient ,cardiovascular diseases ,Sinus (anatomy) ,Cardiac imaging ,business.industry ,medicine.disease ,medicine.anatomical_structure ,Great arteries ,cardiovascular system ,Cardiology ,Cardiology and Cardiovascular Medicine ,business - Abstract
The risk for life-threatening arrhythmia in patients with surgically corrected congenital heart disease is very low and is most commonly owing to scar in the area of a repaired ventricular septum defect or ischemia.1 We present a rare case of scar-related ventricular tachycardia (VT) in the area of the sinus of Valsalva (SV) late after surgically corrected dextro-transposition of the great arteries (d-TGA). Key teaching points • Patients with repaired d-transposition of the great arteries might experience scar-related ventricular tachycardia originating from the aortic root. • Detailed preinterventional imaging is necessary to identify the scar area. • Preinterventional imaging allows to choose the optimal ablation approach from different anatomical sites.
- Published
- 2021
4. Candida bloodstream infection in patients with systemic autoimmune diseases
- Author
-
F. Castaño-Romero, Antoine Berry, Cristina Carbonell, Silvio Ragozzino, Sophie Cassaing, R. Sánchez-González, Alex Soriano, Xavier Iriart, Miguel Marcos, M. Siller-Ruiz, Eléna Charpentier, H.G. Ternavasio-de la Vega, L. Sailler, I. García-García, and M. P. Vaquero-Herrero
- Subjects
Adult ,Male ,medicine.medical_specialty ,Population ,Comorbidity ,Opportunistic Infections ,Autoimmune Diseases ,Systemic autoimmune disease ,Arthritis, Rheumatoid ,Immunocompromised Host ,03 medical and health sciences ,Adrenal Cortex Hormones ,Bloodstream infection ,Internal medicine ,Epidemiology ,medicine ,Humans ,In patient ,education ,Candida albicans ,Aged ,Candida ,Retrospective Studies ,Aged, 80 and over ,Cross Infection ,0303 health sciences ,education.field_of_study ,biology ,030306 microbiology ,business.industry ,Mortality rate ,Candidemia ,Middle Aged ,bacterial infections and mycoses ,biology.organism_classification ,medicine.disease ,Survival Rate ,Methotrexate ,Infectious Diseases ,Spain ,Rheumatoid arthritis ,Female ,France ,business ,Immunosuppressive Agents - Abstract
Objectives To describe the epidemiological, clinical and microbiological characteristics and mortality of patients with Candida bloodstream infection and systemic autoimmune diseases. Methods We performed a retrospective multicenter study of candidemia in adults with systemic autoimmune diseases between 2010 and 2016. Results Among 1040 patients with candidemia, 36 (3.5%) had a systemic autoimmune disease. The most common systemic autoimmune disease was rheumatoid arthritis (27.8%). The most common species was Candida albicans (66.7%). Twenty-two (61.1%) patients received a corticosteroid therapy and nine (25%) received an immunosuppressive therapy at the time of candidemia. The mortality rate was 27.8%. Conclusions Systemic autoimmune diseases are not common in patients with candidemia. The unadjusted mortality rate was comparable to other candidemia studies in the general population.
- Published
- 2020
5. Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study
- Author
-
Gilles Nevez, Brice Autier, Jean-Pierre Gangneux, Yves Cohen, Nadine François, Cécile Aubron, Emmanuel Canet, Sophie Brun, Alexandre Alanio, Philippe Seguin, Nicolas Terzi, Bruno Mégarbane, Jean-François Timsit, Romain Pelletier, Marie Soulié, Dorothée Quinio, Estelle Sabourin, Nicolas de Prost, Juliette Guitard, Frederique Boquel, Valérie Letscher-Bru, Jeff Morcet, Stephan Ehrmann, Guillaume Voiriot, Solène Le Gal, Florent Morio, Bruno Laviolle, Jean-Christophe Richard, Laurent Argaud, Estelle Cateau, Marion Blaize, Matthieu Lesouhaitier, Patrice Le Pape, Carole Schwebel, Florent Wallet, Jordan Leroy, Jean-Ralph Zahar, Ana Novara, Hélène Guegan, Béatrice Riu-Poulenc, Florence Robert-Gangneux, Jean Menotti, Eric Dannaoui, Sorya Belaz, Yves Le Tulzo, Muriel Cornet, Saad Nseir, Ferhat Meziani, Damien Dupont, Boualem Sendid, Antoine Monsel, Florian Reizine, Xavier Iriart, Francoise Botterel, Arnaud Fekkar, Charles-Edouard Luyt, Cécile Garnaud, Melek Manai, Lionel Lamhaut, Jean-Marc Tadié, Julien Mayaux, Sylvie Paulus, Florence Persat, Marie-Elisabeth Bougnoux, Christophe Hennequin, Christine Bonnal, Arnaud W. Thille, Antoine Berry, Sandrine Houze, Guillaume Desoubeaux, Centre Hospitalier Universitaire [Rennes], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Henri Mondor, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Lille, Hospices Civils de Lyon (HCL), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Hôpital Avicenne [AP-HP], Hôpitaux Universitaire Saint-Louis, Lariboisière, Fernand-Widal, Centre Hospitalier Universitaire [Grenoble] (CHU), CHU Necker - Enfants Malades [AP-HP], CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre d’Etude des Pathologies Respiratoires (CEPR), UMR 1100 (CEPR), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Antoine [AP-HP], Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), CHU Strasbourg, and CarMeN, laboratoire
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Multivariate analysis ,Coronavirus disease 2019 (COVID-19) ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,Population ,Intensive care ,Internal medicine ,medicine ,Humans ,education ,Mechanical ventilation ,education.field_of_study ,Coinfection ,SARS-CoV-2 ,business.industry ,Mucormycosis ,COVID-19 ,Articles ,Odds ratio ,medicine.disease ,[SDV] Life Sciences [q-bio] ,Mycoses ,business ,Cohort study - Abstract
International audience; BACKGROUND: Patients with severe COVID-19 have emerged as a population at high risk of invasive fungal infections (IFIs). However, to our knowledge, the prevalence of IFIs has not yet been assessed in large populations of mechanically ventilated patients. We aimed to identify the prevalence, risk factors, and mortality associated with IFIs in mechanically ventilated patients with COVID-19 under intensive care. METHODS: We performed a national, multicentre, observational cohort study in 18 French intensive care units (ICUs). We retrospectively and prospectively enrolled adult patients (aged ≥18 years) with RT-PCR-confirmed SARS-CoV-2 infection and requiring mechanical ventilation for acute respiratory distress syndrome, with all demographic and clinical and biological follow-up data anonymised and collected from electronic case report forms. Patients were systematically screened for respiratory fungal microorganisms once or twice a week during the period of mechanical ventilation up to ICU discharge. The primary outcome was the prevalence of IFIs in all eligible participants with a minimum of three microbiological samples screened during ICU admission, with proven or probable (pr/pb) COVID-19-associated pulmonary aspergillosis (CAPA) classified according to the recent ECMM/ISHAM definitions. Secondary outcomes were risk factors of pr/pb CAPA, ICU mortality between the pr/pb CAPA and non-pr/pb CAPA groups, and associations of pr/pb CAPA and related variables with ICU mortality, identified by regression models. The MYCOVID study is registered with ClinicalTrials.gov, NCT04368221. FINDINGS: Between Feb 29 and July 9, 2020, we enrolled 565 mechanically ventilated patients with COVID-19. 509 patients with at least three screening samples were analysed (mean age 59·4 years [SD 12·5], 400 [79%] men). 128 (25%) patients had 138 episodes of pr/pb or possible IFIs. 76 (15%) patients fulfilled the criteria for pr/pb CAPA. According to multivariate analysis, age older than 62 years (odds ratio [OR] 2·34 [95% CI 1·39-3·92], p=0·0013), treatment with dexamethasone and anti-IL-6 (OR 2·71 [1·12-6·56], p=0·027), and long duration of mechanical ventilation (\textgreater14 days; OR 2·16 [1·14-4·09], p=0·019) were independently associated with pr/pb CAPA. 38 (7%) patients had one or more other pr/pb IFIs: 32 (6%) had candidaemia, six (1%) had invasive mucormycosis, and one (\textless1%) had invasive fusariosis. Multivariate analysis of associations with death, adjusted for candidaemia, for the 509 patients identified three significant factors: age older than 62 years (hazard ratio [HR] 1·71 [95% CI 1·26-2·32], p=0·0005), solid organ transplantation (HR 2·46 [1·53-3·95], p=0·0002), and pr/pb CAPA (HR 1·45 [95% CI 1·03-2·03], p=0·033). At time of ICU discharge, survival curves showed that overall ICU mortality was significantly higher in patients with pr/pb CAPA than in those without, at 61·8% (95% CI 50·0-72·8) versus 32·1% (27·7-36·7; p\textless0·0001). INTERPRETATION: This study shows the high prevalence of invasive pulmonary aspergillosis and candidaemia and high mortality associated with pr/pb CAPA in mechanically ventilated patients with COVID-19. These findings highlight the need for active surveillance of fungal pathogens in patients with severe COVID-19. FUNDING: Pfizer.
- Published
- 2022
6. Ultra–High-Density Activation Mapping to Aid Isthmus Identification of Atrial Tachycardias in Congenital Heart Disease
- Author
-
Arnaud Denis, Philippe Maury, Stephen Murray, Michael Wolf, Antonio Frontera, Pierre Jaïs, Vivienne Ezzat, Nicholas Klotz, Claire A. Martin, Hubert Cochet, Neil Seller, Gregoire Massouillie, Josselin Duchateau, Simon Claridge, Nicolas Combes, Jean-Benoit Thambo, Ewen Shepherd, Felix Bourier, Ghassen Cheniti, Parag R Gajendragadkar, Ruairidh Martin, Simon P. Fynn, Xavier Iriart, David Begley, Patrick M. Heck, Mélèze Hocini, Michel Haïssaguerre, Thomas Pambrun, Richard Snowdon, Frederic Sacher, Martin Lowe, Shohreh Honarbakhsh, Anna Lam, Konstantinos Vlachos, Vinit Sawhney, Nathaniel Thompson, Masateru Takigawa, Arthur M. Yue, Nicolas Derval, and Takeshi Kitamura
- Subjects
Adult ,Heart Defects, Congenital ,Male ,Tachycardia ,medicine.medical_specialty ,Heart disease ,medicine.medical_treatment ,Catheter ablation ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Prospective Studies ,cardiovascular diseases ,030212 general & internal medicine ,Coronary sinus ,Atrial tachycardia ,Aged ,Tetralogy of Fallot ,Tricuspid valve ,business.industry ,Heart ,Equipment Design ,Middle Aged ,medicine.disease ,medicine.anatomical_structure ,Great arteries ,Catheter Ablation ,cardiovascular system ,Cardiology ,Female ,medicine.symptom ,Electrophysiologic Techniques, Cardiac ,business - Abstract
Objectives A new electroanatomic mapping system (Rhythmia, Boston Scientific, Marlborough, Massachusetts) using a 64-electrode mapping basket is now available; we systematically assessed its use in complex congenital heart disease (CHD). Background The incidence of atrial arrhythmias post-surgery for CHD is high. Catheter ablation has emerged as an effective treatment, but is hampered by limitations in the mapping system’s ability to accurately define the tachycardia circuit. Methods Mapping and ablation data of 61 patients with CHD (35 males, age 45 ± 14 years) from 8 tertiary centers were reviewed. Results Causes were as follows: Transposition of Great Arteries (atrial switch) (n = 7); univentricular physiology (Fontans) (n = 8); Tetralogy of Fallot (n = 10); atrial septal defect (ASD) repair (n = 15); tricuspid valve (TV) anomalies (n = 10); and other (n = 11). The total number of atrial arrhythmias was 86. Circuits were predominantly around the tricuspid valve (n = 37), atriotomy scar (n = 10), or ASD patch (n = 4). Although the majority of peri-tricuspid circuits were cavo-tricuspid-isthmus dependent (n = 30), they could follow a complex route between the annulus and septal resection, ASD patch, coronary sinus, or atriotomy. Immediate ablation success was achieved in all but 2 cases; with follow-up of 12 ± 8 months, 7 patients had recurrence. Conclusions We demonstrate the feasibility of the basket catheter for mapping complex CHD arrhythmias, including with transbaffle and transhepatic access. Although the circuits often involve predictable anatomic landmarks, the precise critical isthmus is often difficult to predict empirically. Ultra–high-density mapping enables elucidation of circuits in this complex anatomy and allows successful treatment at the isthmus with a minimal lesion set.
- Published
- 2019
7. Identification of Predictive Markers and Outcomes of Late-onset Pneumocystis jirovecii Pneumonia in Kidney Transplant Recipients
- Author
-
Benjamin Taton, Isabelle Accoceberry, Xavier Iriart, Julie Belliere, Jonathan Visentin, Eléna Charpentier, Arnaud Del Bello, Pierre Merville, Laure Burguet, Marco Gregori, Lionel Couzi, Laurence Delhaes, Stéphane Poirot-Mazères, Nassim Kamar, Hannah Kaminski, Immunology from Concept and Experiments to Translation (ImmunoConcept), Centre National de la Recherche Scientifique (CNRS)-Université de Bordeaux (UB), CHU de Bordeaux Pellegrin [Bordeaux], Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, CHU Toulouse [Toulouse], Institut de Mathématiques de Bordeaux (IMB), Université Bordeaux Segalen - Bordeaux 2-Université Sciences et Technologies - Bordeaux 1-Université de Bordeaux (UB)-Institut Polytechnique de Bordeaux (Bordeaux INP)-Centre National de la Recherche Scientifique (CNRS), Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,Opportunistic infection ,medicine.drug_class ,Lymphocyte ,030106 microbiology ,kidney transplantation ,Pneumocystis carinii ,Pneumocystis pneumonia ,corticosteroid boluses ,03 medical and health sciences ,0302 clinical medicine ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Kidney transplantation ,Retrospective Studies ,Predictive marker ,business.industry ,Pneumonia, Pneumocystis ,lymphopenia ,medicine.disease ,Transplant Recipients ,3. Good health ,Transplantation ,Pneumonia ,Infectious Diseases ,medicine.anatomical_structure ,Case-Control Studies ,Corticosteroid ,business - Abstract
BackgroundIn the era of prophylaxis, Pneumocystis pneumonia (PCP) has become a late-onset opportunistic infection requiring indications for prolonged prophylaxis to be defined. The primary objective of our study was therefore to evaluate risk factors associated with late-onset PCP. The secondary objective was to assess the impact of this infection on graft and patient survival.MethodsWe conducted a French case-control study in Bordeaux and Toulouse center by matching 1 case to 1–2 controls from the same center based on the transplant date and the type of induction treatment.ResultsSeventy cases and 134 controls were included. PCP occurred at a median of 3 years after transplantation. The total lymphocyte count and CD4+ and CD8+ T-lymphocyte values were lower in the cases than in their matched controls on the day of infection and annually up to 4 years earlier. The covariables independently associated with PCP were the total lymphocyte count 1 year before Pneumocystis, mTOR inhibitors used as maintenance immunosuppressive drugs, and the administration of corticosteroid boluses used in acute rejection. A total lymphocyte count threshold ConclusionsPneumocystis pneumonia has dramatic consequences in kidney transplant recipients; a targeted prophylaxis based on simple criteria, such as chronic lymphopenia and/or history of corticosteroid boluses, could be useful to avoid life-threatening complications.
- Published
- 2021
8. Correction to 'Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: A national post-authorization pharmacovigilance study'
- Author
-
Naïm Ouldali, Haleh Bagheri, Francesco Salvo, Denise Antona, Antoine Pariente, Claire Leblanc, Martine Tebacher, Joëlle Micallef, Corinne Levy, Robert Cohen, Etienne Javouhey, Brigitte Bader-Meunier, Caroline Ovaert, Sylvain Renolleau, Veronique Hentgen, Isabelle Kone-Paut, Nina Deschamps, Loïc De Pontual, Xavier Iriart, Christelle Gras-Le Guen, Francois Angoulvant, Alexandre Belot, Aurelie Donzeau, Layal El Aridi, Sophie Lety, Bertrand Leboucher, Agnes Baur, Lucas Jeusset, Maelle Selegny, Cristian Fedorczuk, Marion Lajus, Philippe Bensaid, Yacine Laoudi, Charlotte Pons, Anne-Cécile Robert, Camille Beaucourt, Muriel Richard, Etienne Goisque, Olivier Brissaud, Pierre Segretin, Julie Molimard, Marie-Clothilde Orecel, Gregoire Benoit, Lucille Bongiovanni, Margaux Guerder, Robin Pouyau, Jean-Marie De Guillebon De Resnes, Ellia Mezgueldi, Fleur Cour-Andlauer, Come Horvat, Pierre Poinsot, Cecile Frachette, Antoine Ouziel, Yves Gillet, Catherine Barrey, Jacques Brouard, Florence Villedieu, Vathanaksambath Ro, Narcisse Elanga, Vincent Gajdos, Romain Basmaci, Hadile Mutar, Sébastien Rouget, Elodie Nattes, Isabelle Hau, Sandra Biscardi, Houmam El Jurdi, Camille Jung, Denis Semama, Frederic Huet, Anne-Marie Zoccarato, Mayssa Sarakbi, Guillaume Mortamet, Cécile Bost-Bru, Joachim Bassil, Caroline Vinit, Véronique Hentgen, Pascal Leroux, Valérie Bertrand, Caroline Parrod, Irina Craiu, Philippe Durand, Pierre Tissiere, Caroline Claude, Guillaume Morelle, Tamazoust Guiddir, Charlotte Borocco, Frédérique Delion, Camille Guillot, Stéphane Leteurtre, François Dubos, Mylene Jouancastay, Alain Martinot, Valentine Voeusler, Jeanne Languepin, Nathalie Garrec, Arnaud Chalvon Demersay, Aurélie Morand, Emmanuelle Bosdure, Noémie Vanel, Fabrice Ughetto, Fabrice Michel, Marie Caujolle, Renaud Blonde, Jacqueline Nguyen, Olivier Vignaud, Caroline Masserot-Lureau, François Gouraud, Carine Araujo, Tara Ingrao, Sanaa Naji, Mohammed Sehaba, Christine Roche, Aurelia Carbasse, Christophe Milesi, Mustapha Mazeghrane, Sandrine Haupt, Cyril Schweitzer, Benedicte Romefort, Elise Launay, Christèle Gras-Le Guen, Ahmed Ali, Nathalie Blot, Antoine Tran, Anne Rancurel, Mickael Afanetti, Sophie Odorico, Deborah Talmud, Anais Chosidow, Anne-Sophie Romain, Emmanuel Grimprel, Marie Pouletty, Jean Gaschignard, Olivier Corseri, Albert Faye, Isabelle Melki, Camille Ducrocq, Cherine Benzoïd, Johanna Lokmer, Stéphane Dauger, Maryline Chomton, Anna Deho, Fleur Lebourgeois, Fabrice Lesage, Florence Moulin, Laurent Dupic, Yael Pinhas, Agathe Debray, Martin Chalumeau, Véronique Abadie, Pierre Frange, Jeremie F Cohen, Slimane Allali, William Curtis, Zahra Belhadjer, Johanne Auriau, Mathilde Méot, Lucile Houyel, Damien Bonnet, Christophe Delacourt, Brigitte Bader Meunier, Pierre Quartier, Youssef Shaim, Laurence Baril, Samuel Crommelynck, Baptiste Jacquot, Philippe Blanc, Natacha Maledon, Blandine Robert, Camille Loeile, Clémence Cazau, Gauthier Loron, Simona Gaga, Cécile Vittot, Loubna El Nabhani, François Buisson, Muriel Prudent, Hugues Flodrops, Fadhila Mokraoui, Simon Escoda, Laurent Bonnemains, Sarah-Louisa Mahi, Clara Mertes, Joelle Terzic, Julie Helms, Charlotte Idier, Soraya Chenichene, Nicoleta Magdolena Ursulescu, Gladys Beaujour, Abdelhak Hakim, Alice Miquel, Agnès Rey, Arnaud Wiedermann, Anne Charbonneau, Agnès Veauvy-Juven, Alexandrine Ferry, Alexis Mandelcwajg, Alix Rousseau, Amandine Prenant, Anne-Laure Bourneuf, Anne Filleron, Audrey Robine, Arthur Félix, Aude Parizel, Aurélie Labarre, Aymeric Cantais, Barbara Ros, Basile Coulon, Blandine Biot, Bérengère Dalichoux, Benjamin Fournier, Benoit Cagnard, Blandine Vanel, David Brossier, Bruno Ménager, Bruno Ozanne, Carole Marie-Jeanne, Camille Bergerot, Camille Chavy, Camille Guidon, Candice Fabre, Caroline Galeotti, Catherine Baker, Claire Ballot-Schmit, Céline Belleau, Céline Charasse, Caroline Favel, Chadia Toumi, Charlène Ferrandiz, Charlotte Couturier, Charlotte Pouchoux, Maryline Chomton-Cailliez, Charlotte Kevorkian-Verguet, Clément Brunet, Céline Manteau, Clémence Mougey, Coline Santy, Coralie Fitament, Charlotte Petriat, Charlotte Rebelle, Cyril Charron, Maxime Dartus, David Toulorge, Cécile Guillou-Debuisson, Dorann Bartebin, Valérie Klein, E Broustal, E. Desselas, Elodie Marteau, Emmanuelle Bouvrot, Elise Delacroix, Edeline Coinde, Loubna Elnabhani, Elsa Amouyal, Emilie Chaillou, Emeline Gabilly-Bernard, Emilie Ruiz, Emilie Thibault, Emilie Robin, Etienne Darrieux, Eva Blondel, Floriane Socchi, François Cazassus, Fanny Bajolle, Fatma Lacin, Fouad Madhi, Franck Zekre, François Guerin, Gerald Boussicault, Henri Ginies, Gnansounou Magloire, Guilhem Arnold, Ines Coulognon, Iona Sicard-Cras, Jean-Emmanuel Kahn, Jeanne Bordet, Jeanne-Lise Fausser, Jean-François Baleine, Josephine Brice, Julie Gendras, Kaan Pekin, Karine Norbert, Clément Karsenty, Léa Savary, Laurence Martinat, Léa Lesniewski, Lorelei Charbonnier, Louise Alexandre, Lucas Percheron, Marie Vincenti, Manon Lanzini, Margot Grisval, Marianne Mercy, Marie-Emilie Lampin, Marie Desgranges, Marie Duperril, Marie-Clothilde Orcel, Marion Audier, Marion Favier, Mathieu Carpentier, Mathilde Balcean, Mathilde Bonnet, Maurine Jouret, Marie Delattre, Michael Levy, Michael Valensi, Mickael Shum, Morgane Dumortier, Morgane Gelin, Morgane Nemmouchi, Morgane Williaume, M. Sebaha, Nicoleta Genetay-Stanescu, Nathan Giroux, Nicolas Crassard, Neil Derridj, Noemie Lachaume, Oscar Werner, Olivier Guilluy, Olivier Richer, Olivier Tirel, Aurianne Pauvert, Paul Casha, Noémie Perez, Pauline Gras, Pierre-Louis Leger, Marion Pinchou, Pierre Mornand, Prisca Largo, Ramona-Christina Ibanez, Charlotte Roulland, Salam Hadah Albarazi, Said Bichali, Sarah Faton, Amandine Schott, Sébastien Walser, Severine Guillaume, Solene Vincent, Sophie Galene-Gromez, Stanislas Kozisek, Thierry Maugard, Thierry Blanc, Thierry Navarro, Thomas Lauvray, Tamas Kovacs, Valérie Launay, Véronique Despert, Victoria Lhostis, Virginie Gall, Xavier Micaelli, Yasmine Benadjaoud, Zied Matoussi, Hélène Géniaux, Anthony Facile, Tessa Pietri, Pascale Palassin, Sylvine Pinel, Laurent Chouchana, Delphine Callot, and Charlène Boulay
- Subjects
Oncology ,Health Policy ,Internal Medicine - Published
- 2022
9. Characteristics and outcome according to underlying disease in non-AIDS patients with acute respiratory failure due to Pneumocystis pneumonia
- Author
-
Christophe Hennequin, Virginie Lemiale, Julie Bonhomme, Antoine Roux, Xavier Iriart, M. Leterrier, Anne-Pauline Bellanger, Solène Le Gal, Dominique Toubas, Samia Hamane, Danièle Maubon, Isabelle Durand-Joly, Sandrine Valade, Lucie Biard, Eric Maury, Florence Robert-Gangneux, Anne Debourgogne, Denis Pons, Christelle Pomares, Denis Magne, Frédéric Dalle, Gaston Burghi, Elie Azoulay, Antoine Berry, Université Paris Diderot - Paris 7 (UPD7), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de biostatistique et information médicale de l’hôpital Saint Louis (Equipe ECSTRA) (SBIM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut national du cancer [Boulogne] (INCA)-Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université de Paris (UP), Hôpital Foch [Suresnes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Universitaire [Grenoble] (CHU), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Procédés Alimentaires et Microbiologiques [Dijon] (PAM), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Reims (CHU Reims), Hôpital Pasteur [Nice] (CHU), Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Toulouse [Toulouse], Hôpital Claude Huriez [Lille], CHU Lille, CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), French ministry of health, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Université Bourgogne Franche-Comté [COMUE] (UBFC), Université Nice Sophia Antipolis (1965 - 2019) (UNS), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre de Recherche Saint-Antoine (CRSA), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)
- Subjects
0301 basic medicine ,Microbiology (medical) ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Chronic lymphocytic leukemia ,[SDV]Life Sciences [q-bio] ,030106 microbiology ,Pneumocystis pneumonia ,Organ transplantation ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Medical microbiology ,Acquired immunodeficiency syndrome (AIDS) ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Prospective Studies ,Aged ,Outcome ,business.industry ,Pneumocystis ,Pneumonia, Pneumocystis ,Immunosuppression ,General Medicine ,Middle Aged ,medicine.disease ,Hematologic Diseases ,3. Good health ,Leukemia, Lymphoid ,Infectious Diseases ,Acute Disease ,ICU ,Observational study ,Female ,business ,Respiratory Insufficiency - Abstract
International audience; In the non-AIDS group, several underlying conditions and immune defects could lead to different PCP presentations. This study compared PCP presentation and outcome according to the underlying disease. A secondary analysis of a previously published prospective observational study including 544 PCP patients was done. Only non-AIDS patients were included. Underlying disease was defined as chronic lymphocytic leukemia (CLL), organ transplantation, solid cancer, allogeneic hematopoietic stem cell transplant (AHSCT), other hematological diseases, and immunosuppressive treatment. Clinical characteristics and outcomes were compared between groups. Multiple correspondent analyses compared clinical characteristics at diagnosis. Day 30 mortality was analyzed. Three hundred and twenty-one patients were included in the study. The underlying diseases were hematological malignancy (n = 75), AHSCT (n = 14), CLL (n = 19), solid organ transplant (n = 94), solid tumor (n = 39), and immunosuppressive treatment (n = 57). Compared with other underlying diseases, PCP related to CLL was closer to PCP related to AIDS presentation (long duration of symptoms before diagnosis, high level of dyspnea, and low oxygen saturation at diagnosis). Day 30 mortality was associated with underlying disease, oxygen flow, and shock at ICU admission. PCP presentations may vary according to the underlying reason for immunosuppression. Response to treatment and adjuvant steroid therapy should be analyzed regarding this result.
- Published
- 2021
10. Pulmonary Atresia With Ventriculocoronary Arterial Connections and a Large Conoventricular Septal Defect
- Author
-
Pierre-Emmanuel Séguéla, Mansour Mostefa Kara, Jean-Benoit Thambo, Réda Jakamy, Estibaliz Valdeolmillos, Xavier Iriart, and Jean-Baptiste Mouton
- Subjects
medicine.medical_specialty ,congenital, hereditary, and neonatal diseases and abnormalities ,coronary vessel anomaly ,VSD - Ventricular septal defect ,coronary circulation ,Coronary Vessel Anomaly ,right ventricle ,congenital heart defect ,Coronary circulation ,Internal medicine ,medicine ,otorhinolaryngologic diseases ,Diseases of the circulatory (Cardiovascular) system ,In patient ,Developmental anomaly ,PA-IVS, pulmonary atresia with intact ventricular septum ,VSD, ventricular septal defect ,business.industry ,Congenital Mini-Focus Issue ,PA-VSD, pulmonary atresia with ventricular septal defect ,medicine.disease ,ventricular septal defect ,VCAC, ventriculocoronary arterial connection ,pulmonary atresia ,medicine.anatomical_structure ,RC666-701 ,Cardiology ,Case Report: Clinical Case ,Cardiology and Cardiovascular Medicine ,Pulmonary atresia ,business ,Artery - Abstract
Ventriculocoronary arterial connections are typically found in patients with pulmonary atresia with an intact ventricular septum. This report describes a case of ventriculocoronary arterial connections in a patient with pulmonary atresia with a ventricular septal defect. Our case supports recent data suggesting a primary coronary artery developmental anomaly in pulmonary atresia. (Level of Difficulty: Advanced.), Graphical abstract, Ventriculocoronary arterial connections are typically found in patients with pulmonary atresia with an intact ventricular septum. This report…
- Published
- 2019
11. Predictive factors for residual hypertension following aortic coarctation stenting
- Author
-
Xavier Iriart, Xavier Pillois, Jean-Benoit Thambo, Antoine Cremer, Zakaria Jalal, Claire A. Martin, Jeremy Laik, and François Roubertie
- Subjects
Adult ,Male ,Aortic arch ,medicine.medical_specialty ,Adolescent ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Coarctation of the aorta ,030204 cardiovascular system & hematology ,Balloon ,Aortic Coarctation ,Body Mass Index ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Angioplasty ,medicine.artery ,Internal Medicine ,medicine ,Humans ,030212 general & internal medicine ,Retrospective Studies ,business.industry ,Age Factors ,Stent ,Retrospective cohort study ,medicine.disease ,Hypoplasia ,Treatment Outcome ,Blood pressure ,Hypertension ,Cardiology ,Female ,Stents ,Secondary Hypertension ,Cardiology and Cardiovascular Medicine ,business ,Angioplasty, Balloon - Abstract
Native coarctation of the aorta (CoA) and recoarctation (reCoA) after initial surgical repair are frequently associated with hypertension (HT). Most CoA cases are amenable to transcatheter balloon angioplasty with stent implantation; however, the impact of stenting on arterial blood pressure (BP) is variable. We carried out a retrospective study to identify the predictive factors for residual HT despite optimal endovascular treatment. Patients who had undergone stent implantation for native CoA or reCoA with a pressure gradient of >20 mm Hg between the upper and lower limbs, between 2007 and 2015, were included. The geometry and level of hypoplasia of the aortic arch were determined by non‐invasive imaging, and BP measurements were performed pre‐ and post‐procedure. Thirty consecutive patients (median age: 18.5 years; 76.7% male) were included. Twenty‐three patients had HT before the procedure and 14 (46.7%) had post‐procedural HT despite optimal endovascular treatment. Residual HT post‐stenting was associated with longer stent length and gothic arch geometry. Age and body mass index (BMI) were also associated with residual HT. The pathologic association of abnormal arch geometry and aortic stent placement may lead to a loss of aortic compliance that is further increased by high BMI and older age. Determination of a patient's aortic arch anatomy and clinical profile can assist in defining those at high risk of residual HT despite optimized isthmic stent implantation.
- Published
- 2018
12. Toward the integration of global longitudinal strain analysis in the assessment of neonatal aortic coarctation? A preliminary study
- Author
-
Xavier Pillois, Léa Faydi, Eric Dumas-de-la-Roque, Zakaria Jalal, Jean-Baptiste Mouton, Pierre-Emmanuel Séguéla, Julie Thomas-Chabaneix, François Roubertie, Olivier Tandonnet, Jean-Benoit Thambo, and Xavier Iriart
- Subjects
Aortic arch ,medicine.medical_specialty ,Coarctation of the aorta ,Speckle tracking echocardiography ,030204 cardiovascular system & hematology ,Aortic Coarctation ,Ventricular Function, Left ,Ventricular Outflow Obstruction ,03 medical and health sciences ,0302 clinical medicine ,Bicuspid aortic valve ,Predictive Value of Tests ,Ductus arteriosus ,Internal medicine ,medicine.artery ,medicine ,Humans ,Prospective Studies ,030212 general & internal medicine ,Prospective cohort study ,Ductus Arteriosus, Patent ,business.industry ,Infant, Newborn ,Reproducibility of Results ,Gestational age ,General Medicine ,medicine.disease ,Myocardial Contraction ,Biomechanical Phenomena ,medicine.anatomical_structure ,Echocardiography ,Case-Control Studies ,Predictive value of tests ,Cardiology ,Feasibility Studies ,France ,Cardiology and Cardiovascular Medicine ,business ,Preliminary Data - Abstract
Summary Background Coarctation of the aorta (CoA) is still challenging to diagnose in neonates with patent ductus arteriosus (PDA). Speckle tracking echocardiography allows reliable analysis of myocardial deformation in newborns and seems to provide important insides into regional changes in patients with left ventricular (LV) outflow tract obstruction. Aims To assess the interest of LV global longitudinal strain (GLS) measurement for predicting CoA in neonates with PDA and prenatal suspicion. Methods Prospective single-center study. Twenty-two newborns with prenatal suspicion of CoA were included. All newborns were evaluated in the first 12 hours of life. To assess the feasibility and the reproducibility of GLS, 14 healthy full-term newborns with PDA (group 3) were screened. CoA was diagnosed when DA closed, according to usual echocardiographic criteria. Results Six neonates developed CoA after DA closure (group 1) whereas 16 did not (group 2). Mean gestational age and birth weight were not different between the groups. GLS measurements were possible in 100%. Intra- and inter-observer variability of strain measurements was acceptable. GLS values were significantly lower in neonates who developed CoA (P = 0.015). To predict CoA, cut-off value of −17.42% gave the best compromise for sensitivity (83%) and specificity (72%). Aortic arch dimensions were modestly correlated with strain values. The presence of a bicuspid aortic valve was not associated with significant lower GLS values. Conclusion LV GLS analysis is a feasible and reproducible echocardiographic technique in newborns with PDA. Newborns who will develop CoA seem to have lower values of GLS than healthy neonates. Further studies are needed to confirm these preliminary results.
- Published
- 2018
13. Cost-effectiveness analysis of patent foramen ovale closure with Amplatzer plus medical therapy compared to medical therapy in patients with a history of stroke in France
- Author
-
Amel Allou, Louise Baschet, Luc Lorgis, Gilles Montalscot, Charles Sabourin, and Xavier Iriart
- Subjects
Adult ,medicine.medical_specialty ,Cardiac Catheterization ,Septal Occluder Device ,Cost-Benefit Analysis ,Population ,Foramen Ovale, Patent ,Recurrence ,Internal medicine ,Foramen ,medicine ,Secondary Prevention ,Humans ,In patient ,education ,Stroke ,health care economics and organizations ,education.field_of_study ,business.industry ,Cost-effectiveness analysis ,medicine.disease ,Quality-adjusted life year ,Treatment Outcome ,Cardiology ,Patent foramen ovale ,Quality-Adjusted Life Years ,Cardiology and Cardiovascular Medicine ,business ,Medical therapy - Abstract
Background A patent foramen ovale (PFO) is formed when the ovale foramen does not close spontaneously or re-opens leaving the right and left atrium connected. The present study was conducted to analyze the cost-effectiveness of PFO closure with Amplatzer device plus medical therapy (MT) compared to MT alone in the French reimbursement system for PFO patients with a prior history of stroke, using the RESPECT study data. Methods A multi-state Markov model was used. The analysis was conducted from a collective perspective over a 10-year time horizon with 4% discount applied for costs and health effects. The simulated population included adult patients with PFO. Sub-group analysis was limited to patients with atrial septal aneurysm and/or a large-shunt. Clinical inputs were derived from the RESPECT study and literature. Costs associated with the device, drugs, and management were sourced from literature and national databases. The outcomes of analyses included life-years (LYs), quality-adjusted LYs (QALYs), incremental cost-effectiveness ratio (ICER), and number of recurrent strokes avoided. Scenario and sensitivity analyses were conducted to assess the robustness of the results. Results The use of Amplatzer plus MT provided additional QALYs (0.16) at an incremental cost of 7301€, generating an ICER of 46,288€/QALY for Amplatzer vs. MT alone. In the sub-group analysis, Amplatzer plus MT provided additional QALYs (0.20) at an incremental cost of 5818€, generating an ICER of 28,624€/QALY for Amplatzer plus MT vs. MT alone. Amplatzer plus MT led to lower number of recurrent strokes in comparison to MT alone in both populations. Scenario and sensitivity analyses confirmed the robustness of the results. Conclusion Amplatzer plus MT represents a cost-effective treatment option and is associated with lower stroke recurrence compared to MT alone for PFO patients with a prior history of stroke.
- Published
- 2021
14. Reliability of echocardiographic parameters of the systemic right ventricle systolic function: A prospective multicentre study
- Author
-
Hamouda Abassi, Sophie Pierard, Agnes Pasquet, Xavier Iriart, Charlene Bredy, J.B. Thambo, Marie-Christine Picot, Victor Pommier, Pascal Amedro, Helena Huguet, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
- Subjects
medicine.medical_specialty ,Heart disease ,Intraclass correlation ,Exercise test ,[SDV]Life Sciences [q-bio] ,Systolic function ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Medicine ,Diseases of the circulatory (Cardiovascular) system ,030212 general & internal medicine ,Prospective cohort study ,Reliability (statistics) ,ComputingMilieux_MISCELLANEOUS ,Congenital heart disease ,Reproducibility ,business.industry ,Ultrasound ,Systemic right ventricle ,medicine.disease ,3. Good health ,Oxygen uptake ,medicine.anatomical_structure ,Ventricle ,Echocardiography ,RC666-701 ,Cardiology ,business ,Cardiology and Cardiovascular Medicine ,Software - Abstract
Backgrounds Systemic right ventricle (RV) is a rare and complex form of congenital heart disease (CHD) with a prognosis related to RV dysfunction and impaired physical capacity. Routine follow-up relies on echocardiography, however the prognostic value of echocardiography parameters remains under debate. Real-life patient follow-up involves different ultrasound systems. We aimed to evaluate echocardiography parameters’ reliability in systemic RV, in terms of reproducibility, using vendor-independent software, and in terms prediction of physical capacity impairment. Methods Adult patients with D-transposition of the great artery (d-TGA) who underwent atrial switch or with congenitally-corrected TGA (cc-TGA) were included in this multicentre prospective study. Current echocardiography parameters were analysed using TomTec-Arena™ software. Intraclass correlation coefficients (ICC) assessed inter- and intraobserver reliability. Associations between the most reproducible echocardiography parameters and exercise capacity (peak VO2, VE/VCO2 slope) were explored. Results A total of 47 patients were included in the study (87% d-TGA, median age 36.4 ± 8 years). Conventional and 2D strain echocardiography parameters indicated the existence of a RV dysfunction (TAPSE = 12.8 ± 3.1 mm; RV free wall longitudinal 2D strain = −13.6 ± 3.9%). Good reproducibility (ICC > 0.75) for both intra and interobserver variability was observed in 8 RV echocardiography parameters. Only the TAPSE was significantly associated with peak VO2 (r = 0.4, P = 0.02). Conclusions In this prospective study mimicking real-life echocardiography follow-up of systemic RV, TAPSE, RV free wall longitudinal 2D strain and peak systolic S wave, were the most reproducible echocardiography parameters. However, only the TAPSE was associated with peak VO2.
- Published
- 2021
15. Edge to edge repair using a MitraClip for severe tricuspid valve regurgitation after a Mustard operation
- Author
-
Patrice Guerin, Zakaria Jalal, Jean-Benoit Thambo, and Xavier Iriart
- Subjects
medicine.medical_specialty ,Percutaneous ,medicine.medical_treatment ,Echocardiography, Three-Dimensional ,Catheter ablation ,Regurgitation (circulation) ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,cardiovascular diseases ,030212 general & internal medicine ,Ejection fraction ,business.industry ,MitraClip ,General Medicine ,Middle Aged ,medicine.disease ,Tricuspid Valve Insufficiency ,Arterial Switch Operation ,Treatment Outcome ,cardiovascular system ,Cardiology ,Tricuspid Valve Regurgitation ,Cardiology and Cardiovascular Medicine ,business ,Shunt (electrical) ,Atrial flutter ,Echocardiography, Transesophageal - Abstract
A 48-year-old who underwent a Mustard operation in 1972 followed by a second cardiac intervention in 1996 for pulmonary venous baffle enlargement and residual baffle leak closure, complicated by recurrent atrial flutter, was admitted to our institution for severe systemic atrio-ventricular valve regurgitation (SAVVR) associated with severely impaired systemic right ventricular (RV) function. After careful preoperative anatomic assessment including three-dimensional transesophageal echocardiography (3DTEE) to define the clipping strategy and computed tomography to optimize the transvenous baffle puncture site, the intervention was performed under general anesthesia, fluoroscopic, and 3DTEE guidance. One XTR MitraClip was successfully implanted, achieving a significant reduction in regurgitation and immediate clinical improvement. The transbaffle puncture was closed using an 8 mm atrial septal defect (ASD) device without residual shunt or obstruction of the venous baffle. Post-operative clinical evaluation showed immediate improvement in the NYHA functional class (from III to II), but the patient presented with recurrent flutter at 1 week after the procedure, which was successfully treated by catheter ablation with another transbaffle approach next to the ASD device. Clinical improvement was maintained at 1- and 6-month follow-up with significant reduction in SAVVR, reduced systemic RV volumes and improved RV ejection fraction. This case demonstrates the feasibility of percutaneous treatment of systemic SAVV in patients with systemic RV after atrial redirection.
- Published
- 2021
16. Microsporidiosis after liver transplantation: A French nationwide retrospective study
- Author
-
Jérôme, Dumortier, Sylvie, Radenne, Nassim, Kamar, Filomena, Conti, Armand, Abergel, Audrey, Coilly, Claire, Francoz, Pauline, Houssel-Debry, Claire, Vanlemmens, Noémie, Laverdure, Christophe, Duvoux, Xavier, Iriart, Marc, Thellier, Adela, Angoulvant, Nicolas, Argy, Brice, Autier, Anne-Pauline, Bellanger, Françoise, Botterel, Cyril, Garrouste, Meja, Rabodonirina, Philippe, Poirier, Perraud, Estelle, Hospices Civils de Lyon (HCL), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pascal (IP), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne), Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA), Physiopathologie et traitement des maladies du foie, Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, CHU Pontchaillou [Rennes], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Hôpital Femme Mère Enfant [CHU - HCL] (HFME), AP-HP, Hôpital Henri-Mondor Albert-Chenevier, Service d'Immunologie Clinique et Maladies Infectieuses 94000 Créteil, France, Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), École des Hautes Études en Santé Publique [EHESP] (EHESP), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Clermont-Ferrand, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université d'Angers (UA)-Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
- Subjects
Graft Rejection ,medicine.medical_specialty ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,030230 surgery ,Liver transplantation ,Microsporidiosis ,Gastroenterology ,Tacrolimus ,Albendazole ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Fumagillin ,Child ,Dialysis ,Retrospective Studies ,Transplantation ,liver transplantation ,business.industry ,Retrospective cohort study ,Organ Transplantation ,Middle Aged ,medicine.disease ,3. Good health ,Diarrhea ,Infectious Diseases ,microsporidiosis ,Cyclosporine ,030211 gastroenterology & hepatology ,medicine.symptom ,business ,Immunosuppressive Agents ,medicine.drug - Abstract
International audience; Background: Microsporidiosis has been largely reported in patients with acquired immunodeficiency syndrome, but emerged as a cause of persistent diarrhea in solid organ transplant patients.Methods: Through the French Microsporidiosis Network and the Groupe français de recherche en greffe de foie, we collected all microsporidiosis cases identified in liver transplant patients between 1995 and 2020 in France.Results: We identified 24 liver transplant recipients with microsporidiosis. Sex ratio was balanced and median age was 58.8 (3.5-83.5) years (there were 4 children). Microsporidiosis occurred at a median time of 3.9 (0.1-18.9) years post-transplant. Median duration of diarrhea before diagnosis was 22 days (12-45). Therapeutic care included immunosuppressive therapy changes in 20 patients, as follows: stop cyclosporine or tacrolimus (n = 2), dose reduction of cyclosporine or tacrolimus (n = 12), stop MMF (n = 5), and dose reduction of corticosteroids (n = 1). In addition, 15 patients received specific therapy against microsporidiosis: fumagillin (n = 11) or albendazole (n = 4). Median duration of treatment was 14 days (8-45 days). Finally, 7 patients had immunosuppressive treatment tapering only. Microsporidiosis was complicated by renal failure in 15 patients, requiring dialysis in one case. Two patients had infection relapse. No patient presented proven rejection within the 3 months after microsporidiosis. None of the patients died within the 3 months after microsporidiosis.Conclusions: Microsporidiosis is a very rare infection after liver transplantation but can induce severe dehydration and renal failure. Therefore, it must be systematically sought in any case of persistent diarrhea after first line screening of frequent infectious causes.
- Published
- 2021
17. Cardiovascular events in perimembranous ventricular septal defect with left ventricular volume overload: a French prospective cohort study (FRANCISCO)
- Author
-
Damien Bonnet, Ali Houeijeh, Gilles Bosser, Clément Karsenty, Pamela Moceri, Pauline Helms, Lisa Guirgis, Elise Barre, Quentin Hauet, Sébastien Hascoët, Khaled Hadeed, Virginie Lambert, Xavier Iriart, Nicolas Pangaud, Bérangère Urbina-Hiel, Meriem Mostefa-Kara, Charlotte Denis, Eric Hery, Zakaria Jalal, Nadir Benbrik, Pierre Mauran, Pascale Maragnes, Hugues Lucron, Pascal Amedro, Céline Gronier, Francisco investigators, Magalie Ladouceur, Stéphanie Douchin, François Godart, Bruno Lefort, Karine Warin Fresse, Jean Benoit Thambo, Maurice Guirgis, Diala Khraiche, Adeline Basquin, Daniela Laux, Ronan Bonefoy, Estibaliz Valdeolmillos, Ivan Bouzguenda, Caroline Ovaert, Antoine Legendre, Laurence Iserin, Samir Harchaoui, Laurence Cohen, Jean Marc Lupoglazoff, Bertrand Leobon, Anne-Sophie Leborgne, Carine Vastel, Aurélie Chalard, Nicolas Combes, Alban-Elouen Baruteau, Hélène Ansquer, Guy Vaksmann, Lucile Houyel, Claire Bertail, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
- Subjects
Heart Septal Defects, Ventricular ,Cardiac Catheterization ,medicine.medical_specialty ,Septal Occluder Device ,Heart Ventricles ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,Volume overload ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Ventricular outflow tract ,Prospective Studies ,030212 general & internal medicine ,Child ,Prospective cohort study ,Stroke ,Heart Failure ,business.industry ,General Medicine ,medicine.disease ,Haemolysis ,3. Good health ,Observational Studies as Topic ,Treatment Outcome ,Child, Preschool ,Heart failure ,Pediatrics, Perinatology and Child Health ,Cardiology ,Cardiology and Cardiovascular Medicine ,business ,Watchful waiting ,Cohort study - Abstract
The long-term prospective multi-centre nationwide (French) observational study FRANCISCO will provide new information on perimembranous ventricular septal defect with left ventricular overload but no pulmonary hypertension in children older than 1 year. Outcomes will be compared according to treatment strategy (watchful waiting, surgical closure, or percutaneous closure) and anatomic features of the defect. The results are expected to provide additional guidance about the optimal treatment of this specific population, which is unclear at present. Background The management of paediatric isolated perimembranous ventricular septal defect (pmVSD) with left ventricle (LV) volume overload but no pulmonary arterial hypertension (PAH) remains controversial. Three therapeutic approaches are considered: watchful waiting, surgical closure, and percutaneous closure. We aim to investigate the long-term outcomes of these patients according to anatomic pmVSD characteristics and treatment strategy. Methods The Filiale de Cardiologie Pediatrique et Congenitale (FCPC) designed the FRANCISCO registry, a long-term prospective nationwide multi-centre observational cohort study sponsored by the French Society of Cardiology, which enrolled, over 2 years (2018–2020), patients older than 1 year who had isolated pmVSD with LV volume overload. Prevalent complications related to pmVSD at baseline were exclusion criteria. Clinical, echocardiographic, and functional data will be collected at inclusion then after 1, 5, and 10 years. A core lab will analyse all baseline echocardiographic data to depict anatomical pmVSD features. The primary outcome is the 5-year incidence of cardiovascular events (infective endocarditis, sub-aortic stenosis, aortic regurgitation, right ventricular outflow tract stenosis, tricuspid regurgitation, PAH, arrhythmia, stroke, haemolysis, heart failure, or death from a cardiovascular event). We plan to enrol 200 patients, given the 10% estimated 5-year incidence of cardiovascular events with a 95% confidence interval of ±5%. Associations linking anatomical pmVSD features and treatment strategy to the incidence of complications will be assessed. Conclusions The FRANSCICO study will provide the long-term incidence of complications in patients older than 1 year with pmVSD and LV volume overload. The results are expected to improve guidance for treatment decisions.
- Published
- 2021
18. In-Silico Analysis of the Influence of Pulmonary Vein Configuration on Left Atrial Haemodynamics and Thrombus Formation in a Large Cohort
- Author
-
Andy L. Olivares, Josquin Harrison, Benoit Legghe, Xavier Iriart, Jordi Mill, Oscar Camara, Jérôme Noailly, Xabier Morales, Maxime Sermesant, and Hubert Cochet
- Subjects
FOS: Computer and information sciences ,Thrombus formation ,medicine.medical_specialty ,FOS: Physical sciences ,Hemodynamics ,Pulmonary veins ,Computational fluid dynamics ,030204 cardiovascular system & hematology ,030218 nuclear medicine & medical imaging ,Pulmonary vein ,Computational Engineering, Finance, and Science (cs.CE) ,03 medical and health sciences ,0302 clinical medicine ,Left atrial ,Mitral valve ,Internal medicine ,medicine ,Thrombus ,Computer Science - Computational Engineering, Finance, and Science ,business.industry ,Atrial fibrillation ,Blood flow ,medicine.disease ,Physics - Medical Physics ,Large cohort ,Left atrium haemodynamics ,medicine.anatomical_structure ,cardiovascular system ,Cardiology ,Medical Physics (physics.med-ph) ,business - Abstract
Comunicació presentada a: FIMH 2021 11th International Conference, celebrada del 21 al 25 de juny de 2021 a Stanford, CA, USA. Atrial fibrillation (AF) is considered the most common human arrhythmia. Around 99% of thrombi in non-valvular AF are formed in the left atrial appendage (LAA). Studies suggest that abnormal LAA haemodynamics and the subsequently stagnated flow are the factors triggering clot formation. However, the relation between LAA morphology, the blood pattern and the triggering is not fully understood. Moreover, the impact of structures such as the pulmonary veins (PVs) on LA haemodynamics has not been thoroughly studied due to the difficulties of acquiring appropriate data. On the other hand, in-silico studies and flow simulations allow a thorough analysis of haemodynamics, analysing the 4D nature of blood flow patterns under different boundary conditions. However, the reduced number of cases reported on the literature of these studies has been a limitation. The main goal of this work was to study the influence of PVs on left atrium (LA) and LAA haemodynamics. Computational fluid dynamics simulations were run on 52 patients, the largest cohort so far in the literature, where different parameters were individually studied: pulmonary veins orientation and configuration; LAA and LA volumes and its ratio; and flow velocities. Our computational analysis showed how the right pulmonary vein height and angulation have a great influence on LA haemodynamics. Additionally, we found that LAA with great bending with its tip pointing towards the mitral valve could contribute to favour flow stagnation. This work was supported by the Agency for Management of University and Research Grants of the Generalitat de Catalunya under the the Grants for the Contracting of New Research Staff Programme - FI (2020 FI B 00608) and the Spanish Ministry of Economy and Competitiveness under the Programme for the Formation of Doctors (PRE2018-084062), the Maria de Maeztu Units of Excellence Programme (MDM-2015-0502) and the Retos Investigaci´on project (RTI2018-101193-B-I00). Additionally, this work was supported by the H2020 EU SimCardioTest project (Digital transformation in Health and Care SC1- DTH-06-2020; grant agreement No. 101016496) and the European project PARIS (ID35).
- Published
- 2021
19. Scedosporiosis/lomentosporiosis observational study (SOS): Clinical significance of Scedosporium species identification
- Author
-
Boris Melloni, Benoit Roze, Lilia Hasseine, Jacques-Olivier Bay, Laurence Delhaes, Dominique Toubas, Gaelle Guillerm, Xavier Iriart, Thomas Similowski, Valérie Letscher-Bru, Liana Carausu, Adela Angoulvant, Eric Caumes, Marie-Elisabeth Bougnoux, Yves Leprince, Taieb Chouaki, Cécile Molucon-Chabrot, Eric Dannaoui, Hervé Dutronc, Youssef El-Samad, Florent Morio, Morgane Mourguet, Alexandre Alanio, Berengere Gruson, Pierre Cahen, Stéphane Ranque, Anne Boullié, Julie Bonhomme, Violaine Noel, Françoise Dromer, Elisabeth Chachaty, Felipe Suarez, Beate Heym, François Bissuel, Cécile Jensen, Jean-Pierre Gangneux, Emmanuelle Mouchon, Philippe Zann, Patricia Mariani, Bernard Bouteille, Véronique Leflon-Guibout, Dea Garcia-Hermoso, Anne Scemla, Stéphane Blanche, Agnes Lefort, Dorothée Raoux-Barbot, Didier Bronnimann, Olivier Lortholary, Matthieu Revest, Fanny Lanternier, Philippe Poirier, Luc Quaesaet, Marie Machouart, Françoise Botterel-Chartier, Viviane Queyrel-Moranne, Thomas Perpoint, Anne De Tinteniac, Pascale Penn, Ana Presedo, Marie Balsat, Anne Huynh, Lelia Escaut, Noémie Gadaud, Antoine Huguenin, Martine Gari-Toussaint, Sophie Brun, Jean-Marie Forel, Blandine Rammaert, Nicole Desbois, Alain Delmer, Valérie Moal, Arnaud Fekkar, Damien Hoinard, Elizabeth Rivaud, Delphine Lancement, Laurence Pougnet, Valérie Zeller, Jacques Grill, Florence Pasquier, Fabrice Larosa, Jean-François Papon, Nina Arakelyan-Laboure, Thomas Daix, Catherine Cordonnier, Nicolas Limal, Patrick Lutz, Laurence Maulin, Céline Nourrisson, Stéphane Bretagne, Françoise Uettwiller, Florence Ader, Céline Dieval, Nicolas Traversier, Sophie Bayle, Sorya Belaz, Frédéric Villega, Flore Sicre De Fontbrune, Didier Poisson, Olivier Moquet, Guillaume Martin-Blondel, Kamel Laribi, Delphine Horeau-Langlard, Gilles Nevez, Stéphanie Branger, Audrey Hessel, Philippe Herman, Jérémie Orain, Emilie Catherinot, Frédéric Mechai, Cristina Audoly, Frédéric Gabriel, Jean-François Velly, Caroline Fritz, Muriel Alvarez, Romain Guillemain, Pascal Turlure, Grégoire Leclerc, Frederic Pene, Lionel Mannone, Frédéric Grenouillet, Yoann Prevot, Louis-Jean Couderc, Isabelle Degasne, Giovanna Ingenuo, Joséphine Dorin, Florence Persat, Pierre-Marie Roger, Nathalie Brieu, David Boutoille, Pierre Frange, Nicolas Paleiron, Christophe Joubert, Laurent Hustache-Mathieu, Raoul Herbrecht, Frédéric Janvier, Lenaïg Le Clech, Cécile Gautier, Joelle Guitard, Nicolas Durrleman, Romain Guery, Stéphane De Botton, Sophie Cassaing, Marine Paul, Rachel Brault, Claire Briere-Bellier, Catherine Kauffmann-Lacroix, Nicolas Engrand, Audrey Berric, Hôpital Henri Mondor, Diane Bouvry, André Paugam, CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Victor Segalen - Bordeaux 2, Université Paris Cité (UPCité), Mycologie moléculaire - Molecular Mycology, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals (CNRMA), Institut Pasteur [Paris] (IP), Centre d'infectiologie Necker-Pasteur [CHU Necker], Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier du Pays d'Aix, CHU Amiens-Picardie, The National Reference Center for Invasive Mycoses and Antifungals is supported in part by Santé Publique France and Institut Pasteur., Université de Paris (UP), Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris], Institut Pasteur [Paris], and Institut Pasteur [Paris]-CHU Necker - Enfants Malades [AP-HP]
- Subjects
Adult ,Male ,medicine.medical_specialty ,Antifungal Agents ,Adolescent ,LOMENTOSPORA PROLIFICANS ,Lomentospora prolificans ,Microbial Sensitivity Tests ,Neutropenia ,Scedosporium sp ,Scedosporium ,Young Adult ,03 medical and health sciences ,Scedosporium species ,Internal medicine ,Humans ,Medicine ,Clinical significance ,Child ,Mycological Typing Techniques ,scedosporiosis ,Phylogeny ,Fungemia ,[SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology ,Aged ,Retrospective Studies ,030304 developmental biology ,Aged, 80 and over ,0303 health sciences ,030306 microbiology ,business.industry ,Infant, Newborn ,Infant ,Scedosporium apiospermum ,General Medicine ,Middle Aged ,medicine.disease ,cardiovascular localization ,3. Good health ,Infectious Diseases ,Child, Preschool ,outcome ,Female ,Observational study ,France ,business ,Invasive Fungal Infections - Abstract
International audience; Scedosporiosis/lomentosporiosis is a devastating emerging fungal infection. Our objective was to describe the clinical pattern and to analyze whether taxonomic grouping of the species involved was supported by differences in terms of clinical presentations or outcomes. We retrospectively studied cases of invasive scedosporiosis in France from 2005 through 2017 based on isolates characterized by polyphasic approach. We recorded 90 cases, mainly related to Scedosporium apiospermum (n = 48), S. boydii/S. ellipsoideum (n = 20), and Lomentospora prolificans (n = 14). One-third of infections were disseminated, with unexpectedly high rates of cerebral (41%) and cardiovascular (31%) involvement. In light of recent Scedosporium taxonomic revisions, we aimed to study the clinical significance of Scedosporium species identification and report for the first time contrasting clinical presentations between infections caused S. apiospermum, which were associated with malignancies and cutaneous involvement in disseminated infections, and infections caused by S. boydii, which were associated with solid organ transplantation, cerebral infections, fungemia, and early death. The clinical presentation of L. prolificans also differed from that of other species, involving more neutropenic patients, breakthrough infections, fungemia, and disseminated infections. Neutropenia, dissemination, and lack of antifungal prescription were all associated with 3-month mortality. Our data support the distinction between S. apiospermum and S. boydii and between L. prolificans and Scedosporium sp. Our results also underline the importance of the workup to assess dissemination, including cardiovascular system and brain. Lay Summary Scedosporiosis/lomentosporiosis is a devastating emerging fungal infection. Our objective was to describe the clinical pattern and to analyze whether taxonomic grouping of the species involved was supported by differences in terms of clinical presentations or outcomes.
- Published
- 2020
20. Acute Cardiovascular Manifestations in 286 Children with Multisystem Inflammatory Syndrome Associated with COVID-19 Infection in Europe
- Author
-
Andreia Francisco, Phuoc Duong, Shalan Uaid Fadl, Karl Viktor Perminow, Owen Miller, Vladislav Vukomanovic, Marisa Vieira, Gabriela Doros, Savina Mannarino, Israel Valverde, Francisco Gonzalez Barlatay, Maria Ilina, Ornella Milanesi, Beata Kucińska, Irene M. Kuipers, Antigoni Deri, Fernando Centeno, Susana Maria Rey-García, Zdenka Reinhardt, Victoria C. Ziesenitz, Simona Anna Marcora, Ana R. Sousa, Begoña Manso, Moises Rodriguez-Gonzalez, Jussi Niemelä, Jelena Hubrechts, Cecilia Lazea, Gernot Grangl, Joan Sanchez-de-Toledo, Almudena Ortiz-Garrido, Ferran Gran, Daniël De Wolf, Giulia Bordin, Abigail Sharpe, Francesca Cairello, Bernadette Brent, Gauri Nepali, Isabelle Loeckx, Paraskevi Theocharis, Sylvie Di Filippo, Colin J. McMahon, Ashish Chikermane, Emanuela Valsangiacomo-Buchel, Giridhar Soda, Marie-Christine Seghaye, Fatima Pinto, Paolo Ciliberti, Xavier Iriart, Giulia Tuo, Yogen Singh, Wendy Dewals, Constancio Medrano-Lopez, Amalia Tamariz-Martel, Carlo Pace Napoleone, Andrea Donti, Federico Gutierrez-Larraya, and Kristof Vandekerckhove
- Subjects
medicine.medical_specialty ,Ejection fraction ,biology ,business.industry ,030204 cardiovascular system & hematology ,medicine.disease ,Pericardial effusion ,Procalcitonin ,3. Good health ,Ferritin ,03 medical and health sciences ,0302 clinical medicine ,Troponin complex ,Intensive care ,Internal medicine ,Shock (circulatory) ,biology.protein ,medicine ,030212 general & internal medicine ,medicine.symptom ,10. No inequality ,business ,Cardiac imaging - Abstract
Background: The aim of the study was to document cardiovascular clinical findings, cardiac imaging and laboratory markers in children presenting with the novel multisystemic inflammatory syndrome associated with COVID-19. Methods: A real-time internet based survey was sent via the member mailing database for Association for European Paediatric and Congenital Cardiologists (AEPC) working groups for Cardiac Imaging and Cardiovascular Intensive Care member. Inclusion criteria was children 0-18 years admitted to hospital between March 1 and June 6, 2020 with diagnosis of an inflammatory syndrome and acute cardiovascular complications. Findings: A total of 286 children from 55 centres from 17 European countries were included. The median age was 8·4 years (IQR 3·8-12·4 years) and 67% were males. Most common cardiovascular complications were shock (40%), cardiac arrhythmias (35%), pericardial effusion (28%) and coronary artery dilatation (24%). Reduced left ventricular ejection fraction was present in 52% of patients and 93% had raised cardiac troponin (cTnT). The biochemical markers of inflammation were raised in majority of patients on admission: elevated CRP (99%), ferritin (79%), procalcitonin (96%), NT-proBNP (93%), IL-6 level (88%) and D-dimers (90%). There was a statistically significant correlation between degree of elevation in cardiac and biochemical parameters and need of intensive care support (p
- Published
- 2020
21. Evaluation of MucorGenius® mucorales PCR assay for the diagnosis of pulmonary mucormycosis
- Author
-
Jean-Pierre Gangneux, Antoine Berry, Hélène Guegan, Florence Robert-Gangneux, Marie-Elisabeth Bougnoux, Xavier Iriart, Institut de recherche en santé, environnement et travail (Irset), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université d'Angers (UA), CHU Pontchaillou [Rennes], CHU Toulouse [Toulouse], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Jonchère, Laurent
- Subjects
0301 basic medicine ,Microbiology (medical) ,Mucorales ,medicine.medical_specialty ,[SDV]Life Sciences [q-bio] ,030106 microbiology ,Direct examination ,Aspergillosis ,Sensitivity and Specificity ,MESH: Invasive Fungal Infections* / diagnosis ,Gastroenterology ,03 medical and health sciences ,Galactomannan ,chemistry.chemical_compound ,MucorGenius® ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Mucormycosis ,MESH: Mucormycosis* / diagnosis ,Clinical significance ,030212 general & internal medicine ,DNA, Fungal ,Pulmonary mucormycosis ,Retrospective Studies ,Aspergillus ,MESH: Humans ,biology ,business.industry ,biology.organism_classification ,medicine.disease ,MESH: Sensitivity and Specificity ,3. Good health ,[SDV] Life Sciences [q-bio] ,Infectious Diseases ,Real-time polymerase chain reaction ,chemistry ,MESH: DNA, Fungal / genetics ,MESH: Mucorales* / genetics ,Molecular diagnosis ,business ,Invasive Fungal Infections ,Real-time PCR - Abstract
International audience; Objectives - We aimed to assess the clinical relevance of the marketed pan-mucorales real-time PCR assay MucorGenius® (Pathonostics) on pulmonary specimens relative to that of in-house PCR assays and conventional mycology for the diagnosis of mucormycosis. Methods - In total, 319 pulmonary samples from severely immunosuppressed patients at risk for invasive mold disease (IMD) were retrospectively included. Direct examination, mycological culture, and PCR testing were performed using three genus-specific in-house mucorales real-time PCR assays and MucorGenius®PCR. Results from Aspergillus testing, including galactomannan and PCR, were also collected. Results - The 319 patients were graded according to modified EORTC-MSG criteria as proven/probable mucormycosis (n=6), proven/probable invasive aspergillosis (IA) (n=63), Aspergillus-mucorales co-infections (n=4), possible IMD (n=152), and excluded IMD (n=94). The in-house and MucorGenius®PCR assays were positive for 33 (10.3%) and 27 (8.5%) samples, respectively, whereas culture was positive for only 10 (3.1%). The in-house and MucorGenius®PCR assays showed a sensitivity of 100% (10/10) and 90% (9/10) and a specificity of 95.7% and 97.9%, respectively. Both PCR assays allowed the detection of mucorales DNA in samples from 10 possible cases and six IA, all missed by culture. Conclusions - MucorGenius® showed good performance, despite missing some low fungal burden. Combining mucorales PCR with EORTC-MSG criteria greatly improved the diagnosis of mucormycosis.
- Published
- 2020
22. Outcomes of solid organ transplant recipients with invasive aspergillosis and other mold infections
- Author
-
Laurence Lavayssière, Cédric Farges, Federico Sallusto, Joelle Guitard, Eléna Charpentier, Fabrice Muscari, Nassim Kamar, Xavier Iriart, Marie-Béatrice Nogier, Shérazade Lakhdar-Ghazal, Laure Esposito, M. Murris, Camille Dambrin, Arnaud Del Bello, Sophie Cassaing, Olivier Cointault, L. Porte, Anne-Laure Hebral, Stanislas Faguer, Service de Parasitologie et Mycologie, CHU Toulouse [Toulouse]-Institut Fédératif de Biologie (IFB) - Hôpital Purpan, Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Service de Néphrologie - Hypertension Artérielle Dialyse - Transplantation, CHU Toulouse [Toulouse]-Hôpital de Rangueil, Service de pneumologie [Toulouse], CHU Toulouse [Toulouse]-Hôpital Larrey [Toulouse], Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'Urologie - Transplantation Rénale - Andrologie, Hôpital de Rangueil, Service des maladies infectieuses et tropicales [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Fédératif de Biologie (IFB) - Hôpital Purpan, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3)
- Subjects
Male ,medicine.medical_treatment ,Hemodynamics ,MESH: Transplant Recipients ,030230 surgery ,MESH: Female Humans ,Aspergillosis ,Logistic regression ,outcomes ,0302 clinical medicine ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Cumulative incidence ,MESH: Incidence ,solid organ transplantation ,MESH: Treatment Outcome ,Heart transplantation ,MESH: Aged ,Kidney ,MESH: Middle Aged ,Incidence ,Middle Aged ,3. Good health ,Infectious Diseases ,medicine.anatomical_structure ,Treatment Outcome ,Aspergillus ,non-Aspergillus molds ,030211 gastroenterology & hepatology ,Female ,MESH: Invasive Fungal Infections / mortality ,medicine.medical_specialty ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Renal replacement therapy ,Aged ,Retrospective Studies ,Mechanical ventilation ,Transplantation ,invasive aspergillosis ,business.industry ,MESH: Retrospective Studies ,Organ Transplantation ,medicine.disease ,Transplant Recipients ,MESH: Male ,MESH: Aspergillosis / epidemiology ,MESH: Organ Transplantation ,MESH: Invasive Fungal Infections / epidemiology ,business ,Invasive Fungal Infections - Abstract
International audience; Objectives: To characterize the clinical presentation and outcomes of invasive mold infections (IMI) in solid organ transplant (SOT) recipients.Methods: Inclusion of all SOT recipients with IMI diagnosed between 2008 and 2016 at a referral center for SOT. Univariable analyses identified factors associated with death at one year, and logistic regression models retained independent predictors.Results: Of the 1739 patients that received a SOT during this period, 68 developed IMI (invasive aspergillosis [IA] in 58). Cumulative incidence of IMI at 1 year ranged from 1.2% to 18.8% (kidney and heart transplantation, respectively). At baseline, compared with other IMI, the need for vasoactive drugs was more frequent in patients with IA. During follow-up, 35 patients (51%) were admitted to the ICU and required mechanical ventilation (n = 27), vasoactive drugs (n = 31), or renal replacement therapy (n = 31). The need for vasoactive drugs (OR 7.34; P = .003) and a positive direct examination (OR 10.1; P = .004) were independently associated with the risk of death at 1 year in patients with IA (n = 33; 57%) CONCLUSIONS: Characteristics of IMI at presentation varied according to the underlying transplanted organ and the mold species. Following IA, one-year mortality may be predicted by the need for hemodynamic support and initial fungal load
- Published
- 2019
23. Percutaneous edge to edge systemic tricuspid valve repair for the treatment of severe tricuspid valve regurgitation in patients with systemic right ventricle: The first descriptive cohort
- Author
-
Alexandre Silini and Xavier Iriart
- Subjects
medicine.medical_specialty ,Percutaneous ,business.industry ,Regurgitation (circulation) ,medicine.anatomical_structure ,Quality of life ,Ventricle ,Great arteries ,Internal medicine ,Cohort ,medicine ,Cardiology ,Tricuspid Valve Regurgitation ,TRICUSPID VALVE REPAIR ,Cardiology and Cardiovascular Medicine ,business - Abstract
Introduction Patients with systemic right ventricle (mostly congenitally-corrected transposition of the great arteries or transposition of the great arteries corrected by atrial switch) commonly develop significant systemic tricuspid valve regurgitation and systemic right ventricular dysfunction in adulthood, both of which presenting a therapeutic dilemma for the care team. Percutaneous edge-to-edge repair could be a alternative to surgery. Methods Seven high-risk surgical patients with severe systemic tricuspid regurgitation undergoing a percutaneous repair were included between July 2020 and March 2021. Our study is a prospective analysis of short and mid-term clinical, biological, echocardiographic and MRI outcomes with an expected minimum follow-up of 2 years. Results The first data tend to show a significant benefit of the repair on clinical status (dyspnea severity, quality of life, test exercise performance), a decrease of BNP level and an improvement of tricuspid regurgitation and right ventricular volume and function measured by echocardiography and MRI. Besides, the rate of failure and complications seems to be very low. Discussion Percutaneous edge-to-edge repair of systemic tricuspid regurgitation might be a safe and effective therapeutic option in high-risk surgical adult patients.
- Published
- 2021
24. Risk factors for early pulmonary homograft dysfunction in congenital heart disease
- Author
-
Amandine Martin, F. Roubertie, Maëlys Venet, J.B. Thambo, Xavier Iriart, Julie Thomas, Zakaria Jalal, and Bernard Kreitmann
- Subjects
medicine.medical_specialty ,Heart disease ,business.industry ,Extracorporeal circulation ,Retrospective cohort study ,medicine.disease ,Intensive care unit ,law.invention ,law ,Internal medicine ,Clinical endpoint ,medicine ,Cardiology ,Ventricular outflow tract ,Risk factor ,Cardiology and Cardiovascular Medicine ,business ,Survival analysis - Abstract
Background Pulmonary homografts (PH) are used as a first-line treatment for surgical right ventricular outflow tract (RVOT) reconstruction in patients with congenital heart disease (CHD). Despite a better freedom from reintervention than prosthetic conduits, PH are not spared from failure and cases of early dysfunction are regularly described. Aims The aim of this study was to assess the rate of early PH dysfunction in patients of the Bordeaux University Hospital and to identify associated risk factors. Methods A monocentric retrospective study was conducted in children and adults with CHD and PH implantation for RVOT reconstruction. Clinical and echocardiographic data were collected during follow-up. PH dysfunction was defined as a peak of gradient greater than 50 mmHg and/or as pulmonary regurgitation greater than moderate. Early dysfunction was defined as occurring within two years postoperatively. Primary endpoint was the early PH dysfunction rate at 2 years. The dysfunction-free survival curve was calculated according to the Kaplan-Meier method. A logistic regression with univariate then multivariate analysis was performed to identify risk factors for early dysfunction. Results Between January 2002 and November 2020, 112 PH were implanted in 110 patients and 11 cases of homograft dysfunction were reported during the follow-up, including 9 cases of early dysfunction. The rate of early dysfunction was 9.4 [3.3–15.1] % and freedom from reintervention was 94.6 [90.0–99.0] % at two years. The only independent risk factor identified by the multivariate analysis was duration of extracorporeal circulation (P = 0.007) but the length of stay in intensive care unit (P = 0.088) and the initial maximum pulmonary transvalvular gradient (P = 0.06) were also close to significance in the multivariate analysis. Conclusion Although PH provide a durable substitute for RVOT reconstruction, a significant proportion of patients presents early PH dysfunction and requires premature reintervention. An inflammatory mechanism is suspected but dedicated studies should be conducted to validate this hypothesis.
- Published
- 2021
25. Change in biventricular function after cone reconstruction of Ebstein’s anomaly: an echocardiographic study
- Author
-
Sachin Khambadkone, Elodie Perdreau, Marina Hughes, Xavier Iriart, Michael Ibrahim, Victor Tsang, S Kataria, Jan Marek, and K. Janagarajan
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Ventricular Dysfunction, Right ,030204 cardiovascular system & hematology ,Risk Assessment ,Cohort Studies ,Biventricular function ,Young Adult ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,Tricuspid Valve Insufficiency ,Reference Values ,Median follow-up ,Internal medicine ,Ebstein's anomaly ,Image Interpretation, Computer-Assisted ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,030212 general & internal medicine ,Cardiac Surgical Procedures ,Systole ,Child ,Retrospective Studies ,Observer Variation ,business.industry ,Infant ,Retrospective cohort study ,General Medicine ,Middle Aged ,Prognosis ,medicine.disease ,Ebstein Anomaly ,Treatment Outcome ,medicine.anatomical_structure ,Echocardiography ,Ventricle ,Child, Preschool ,Cardiology ,Female ,Tricuspid Valve Regurgitation ,Cardiology and Cardiovascular Medicine ,business - Abstract
Aims The Cone reconstruction in Ebstein's anomaly (EA) aims to reduce tricuspid valve regurgitation (TR) and reposition the valve to the anatomic annulus, but post-operative progress of ventricular function is poorly understood. This study evaluated biventricular function after Cone reconstruction using echocardiographic techniques. Methods and results A retrospective study assessing longitudinal change was conducted from 2009 to 2014. All symptomatic patients with EA and severe TR undergoing surgery were included. Transthoracic advanced echocardiography was performed pre- and post-operatively (at short-term (
- Published
- 2017
26. 86 Long-term outcome of critical aortic valve stenosis
- Author
-
Marina Hugues, Xavier Iriart, Sachin Khambadkone, Richard Issitt, Bea Bonello, Alessandro Giardini, Jan Marek, Victor Tsang, Michelle Carr, and Martin Kostolny
- Subjects
medicine.medical_specialty ,Ejection fraction ,business.industry ,Ross procedure ,medicine.medical_treatment ,Mechanical Aortic Valve ,Endocardial fibroelastosis ,medicine.disease ,Stenosis ,medicine.anatomical_structure ,Ventricle ,Aortic valve stenosis ,Internal medicine ,medicine ,Cardiology ,business ,Survival rate - Abstract
Background Survival with critical aortic valve stenosis (CAS) can be successfully achieved in the short term. Long-term outcome however remains uncertain. We sought to study the long-term survival and reinterventions; exercise capacity and myocardial performance in a subgroup of long-term survivors. Methods Retrospective over 40 years of all patients (n=96) requiring intervention for CAS. A subgroup (n=25) of long-term survivors underwent cardiopulmonary exercise test, echocardiography and magnetic resonance imaging. Results Mean age at first intervention was 9±7.5 days. Early death occurred in 19 (19.8%) and overall reported death was 29 (32.9%). At 20 years, survival rate was 65.8% and freedom from reintervention was 24% (figure 1A and 1B). Median age of our long-term survivors, median age was 15.7±6.4 years, 16(64%) had a Ross procedure and 3(12%) had a mechanical aortic valve. Sixteen patients were in NYHA I, 3 NYHA II, 6 NYHA III. Overall peak VO2 was mildly depressed (84.6±24% predicted; 32.1±8.2 ml/kg/min), normal in 9(45%), severely depressed in 6 (30%). Mean left ventricle (LV) ejection fraction was 65.5±11.22% and mean LV end-diastolic volume Z score was 0.02±1.4. Mean LV outflow tract Vmax was 2.27±1.17 m/s. Four patients (16%) had moderate aortic regurgitation. Mean right ventricular outflow gradient was 19.23±23.57 mmHg. Five patients (20%) had severe LV diastolic dysfunction on echocardiography and confirmed by invasive measurement. Severe diastolic dysfunction was not associated with an older age (p=0.15), small ventricular dimension (p=0.2) or residual obstruction (p=0.39) but was associated with the presence of endocardial fibroelastosis (p=0.00014). Conclusions After an early mortality, long-term survival of patients with critical aortic stenosis is good at the expense of a high rate of reinterventions. Despite a good clinical status, myocardial assessment revealed a high rate of LV diastolic dysfunction that could be a marker of irreversible intrinsic myocardial damage.
- Published
- 2019
27. Pneumocystis Infection Outbreaks in Organ Transplantation Units in France: A Nation-Wide Survey
- Author
-
M. Leterrier, Anne Totet, Céline Damiani, Danièle Maubon, Solène Le Gal, Isabelle Accoceberry, Julie Bonhomme, Pierre Marty, E. Bailly, Ermanno Candolfi, Anne Debourgogne, Laurence Millon, Frédéric Dalle, Anne-Pauline Bellanger, Patrice Le Pape, Denis Pons, Christelle Pomares, Yann Le Meur, Marie Machouard, Marie-Laure Dardé, Laurence Delhaes, Ahmed Abou Bacar, Dominique Toubas, Frédéric Gabriel, Estelle Cateau, Gilles Nevez, Loïc Favennec, Marie-Hélène Rodier, Xavier Iriart, Eric Dannaoui, Laurence Lachaud, Guillaume Desoubeaux, Pierre Flori, Laboratoire Universitaire de Biodiversité et Ecologie Microbienne (LUBEM), Université de Brest (UBO), Laboratoire de Parasitologie et Mycologie (Parasito - Myco - BREST), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Matrice extracellulaire et dynamique cellulaire - UMR 7369 (MEDyC), Université de Reims Champagne-Ardenne (URCA)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Centre National de la Recherche Scientifique (CNRS), Service de parasitologie et de mycologie médicales, Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Laboratoire de parasitologie mycologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Institut de Parasitologie et de Pathologie Tropicale de Strasbourg, Faculté de Médecine de Strasbourg, Université de Strasbourg, CHRU Brest - Service de Nephrologie (CHU - BREST - Nephrologie), Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Service de parasitologie et mycologie [CHU de Besançon], Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Laboratoire Chrono-environnement - UFC (UMR 6249) (LCE), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université de Caen Normandie (UNICAEN), Normandie Université (NU), Microbiologie de l'Eau (MDE), Ecologie et biologie des interactions (EBI), Université de Poitiers-Centre National de la Recherche Scientifique (CNRS)-Université de Poitiers-Centre National de la Recherche Scientifique (CNRS), Institut de Parasitologie et de Pathologie Tropicale, UMR-I 01 - AMIENS, Université de Picardie Jules Verne (UPJV), Unité de Parasitologie-Mycologie [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Université de Limoges (UNILIM), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université de Bordeaux (UB), Centre d’Etude des Pathologies Respiratoires (CEPR), UMR 1100 (CEPR), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Epidémiosurveillance de protozooses à transmission alimentaire et vectorielle (ESCAPE), Université de Reims Champagne-Ardenne (URCA)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), Anofel Cryptosporidium National Network, Institut d'Histoire de la Pensée Classique (IHPC), École normale supérieure - Lyon (ENS Lyon)-Université Lumière - Lyon 2 (UL2)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS), CHU Bordeaux [Bordeaux], Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle (MIVEGEC), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud]), Laboratoire de Microbiologie (CHD de la Roche-Sur-Yon), CHD Vendee (La Roche Sur Yon), Cibles et médicaments de l'infection, de l'immunité et du cancer (IICiMed), Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Nantes (UN)-Université de Nantes (UN), Laboratoire de recherche en Hydrodynamique, Énergétique et Environnement Atmosphérique (LHEEA), École Centrale de Nantes (ECN)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Adaptation et pathogénie des micro-organismes [Grenoble] (LAPM), Université Joseph Fourier - Grenoble 1 (UJF)-Centre National de la Recherche Scientifique (CNRS), Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Gabriel Montpied (CHU), CHU Clermont-Ferrand, Université de Poitiers-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ), SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Centre National de la Recherche Scientifique (CNRS), Departments of Medical Parasitology and Mycology, Service de néphrologie, Sagem - SAFRAN Gr., Université de Strasbourg (UNISTRA), Centre National de Référence (CNR) Toxoplasmose/Toxoplasma Biological Resource Center (BRC) (CNR Toxoplasmose-Toxoplasma BRC), CHU Limoges, Service de Parasitologie-Mycologie [CHRU Nancy], Stress, Immunité, Pathogènes (SIMPA), Université de Lorraine (UL), Appareil Digestif Environnement Nutrition (ADEN ), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Groupe Immunité des Muqueuses et Agents Pathogènes (GIMAP), Université Jean Monnet [Saint-Étienne] (UJM), Service de parasitologie et de mycologie, Institut de Recherche pour le Développement (IRD [France-Sud])-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Centre hospitalier universitaire de Nantes (CHU Nantes), Laboratoire Chrono-environnement - CNRS - UFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Infections Parasitaires : Transmission, Physiopathologie et Thérapeutiques (IP-TPT), Service de Santé des Armées-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)-Institut de Recherche pour le Développement (IRD), Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), Université d'Angers (UA), Laboratoire de Parasitologie et Mycologiede [CHRU Brest], Laboratoire de parasitologie et de mycologie médicales [CHU Amiens], CHU Amiens-Picardie, Service de parasitologie et mycologie [CHRU de Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie-Institut National de l'Environnement Industriel et des Risques, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), CHU Gabriel Montpied [Clermont-Ferrand], Mycologie moléculaire, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Institut d’Histoire des Représentations et des Idées dans les Modernités (IHRIM), Université Lumière - Lyon 2 (UL2)-École normale supérieure - Lyon (ENS Lyon)-Centre National de la Recherche Scientifique (CNRS)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Université Jean Moulin - Lyon 3 (UJML), Université de Lyon-Université de Lyon-Université Clermont Auvergne (UCA)-Université Jean Monnet [Saint-Étienne] (UJM), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Service de Santé des Armées, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Université de Reims Champagne-Ardenne (URCA), and COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,Genotype ,Pneumocystis carinii ,Organ transplantation ,Disease Outbreaks ,03 medical and health sciences ,0302 clinical medicine ,genotypes ,Surveys and Questionnaires ,Internal medicine ,Humans ,Medicine ,Pneumocystis jirovecii ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,030212 general & internal medicine ,Genotyping ,ComputingMilieux_MISCELLANEOUS ,[SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology ,Retrospective Studies ,Transplant recipients ,[SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health ,0303 health sciences ,biology ,030306 microbiology ,business.industry ,Pneumocystis ,Pneumonia, Pneumocystis ,Outbreak ,Organ Transplantation ,biology.organism_classification ,3. Good health ,Transplantation ,Infectious Diseases ,Renal transplant ,France ,business ,Pneumocystis Infections - Abstract
The burden of nosocomial Pneumocystis infections in transplantation units in France was evaluated through a retrospective survey. Over 12 years, 16 outbreaks occurred, including 13 among renal transplant recipients (RTRs). We performed Pneumocystis jirovecii genotyping in 5 outbreaks, which suggested that specific strains may have been selected by RTRs.
- Published
- 2019
28. Real-time PCR for diagnosis of imported schistosomiasis
- Author
-
Sophie Cassaing, Jérôme Boissier, Hélène Guegan, Antoine Berry, Alexis Valentin, Judith Fillaux, Florence Robert-Gangneux, Eléna Charpentier, Jean-Pierre Gangneux, Emilie Guemas, Pamela Chauvin, Xavier Iriart, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service de Parasitologie et Mycologie, CHU Toulouse [Toulouse]-Institut Fédératif de Biologie (IFB) - Hôpital Purpan, Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Interactions Hôtes-Pathogènes-Environnements (IHPE), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Institut Français de Recherche pour l'Exploitation de la Mer (IFREMER)-Université de Perpignan Via Domitia (UPVD), ANR 18 CE35 0001 03, U.S. Department of Defense, Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service de Parasitologie et Mycologie [CHU Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Perpignan Via Domitia (UPVD)-Institut Français de Recherche pour l'Exploitation de la Mer (IFREMER)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Université de Perpignan Via Domitia (UPVD), Institut Français de Recherche pour l'Exploitation de la Mer (IFREMER), Centre National de la Recherche Scientifique (CNRS), Université de Montpellier (UM), ANR-18-CE35-0001,HySWARM,Hybrid Swarm: rôle de l'hybridation dans les capacités invasives, l'épidémiologie et le diagnostic de la schistosomiase(2018), and Modat, Anne
- Subjects
0301 basic medicine ,Schistosoma Mansoni ,Physiology ,Biopsy ,RC955-962 ,Artificial Gene Amplification and Extension ,Urine ,Pathology and Laboratory Medicine ,Gastroenterology ,Polymerase Chain Reaction ,Serology ,MESH: DNA, Helminth / analysis ,Feces ,Schistosomiasis haematobia ,MESH: Biopsy ,0302 clinical medicine ,Arctic medicine. Tropical medicine ,Medicine and Health Sciences ,Schistosomiasis ,MESH: Animals ,MESH: Schistosomiasis haematobia / blood ,MESH: Travel ,ComputingMilieux_MISCELLANEOUS ,Schistosoma haematobium ,Travel ,biology ,[SDV.BID.EVO]Life Sciences [q-bio]/Biodiversity/Populations and Evolution [q-bio.PE] ,Eukaryota ,DNA, Helminth ,6. Clean water ,3. Good health ,Body Fluids ,Infectious Diseases ,Real-time polymerase chain reaction ,Helminth Infections ,Schistosoma ,Schistosoma mansoni ,Anatomy ,Public aspects of medicine ,RA1-1270 ,MESH: Schistosomiasis mansoni / urine ,Research Article ,Neglected Tropical Diseases ,medicine.medical_specialty ,030231 tropical medicine ,Surgical and Invasive Medical Procedures ,MESH: Schistosomiasis mansoni / diagnosis ,MESH: Schistosoma haematobium / isolation & purification ,Real-Time Polymerase Chain Reaction ,Research and Analysis Methods ,Sensitivity and Specificity ,03 medical and health sciences ,Internal medicine ,Helminths ,parasitic diseases ,medicine ,Parasitic Diseases ,[SDV.BID.EVO] Life Sciences [q-bio]/Biodiversity/Populations and Evolution [q-bio.PE] ,Animals ,Humans ,Molecular Biology Techniques ,MESH: Real-Time Polymerase Chain Reaction / methods ,Molecular Biology ,MESH: Humans ,MESH: Schistosomiasis haematobia / urine ,business.industry ,Public Health, Environmental and Occupational Health ,Organisms ,Biology and Life Sciences ,Gold standard (test) ,biology.organism_classification ,medicine.disease ,Tropical Diseases ,Invertebrates ,Schistosoma Haematobium ,MESH: Schistosomiasis haematobia / diagnosis ,Schistosomiasis mansoni ,MESH: Sensitivity and Specificity ,030104 developmental biology ,MESH: Feces / parasitology ,MESH: Schistosomiasis mansoni / blood ,business - Abstract
Background The diagnosis of schistosomiasis currently relies on microscopic detection of schistosome eggs in stool or urine samples and serological assays. The poor sensitivity of standard microscopic procedures performed in routine laboratories, makes molecular detection methods of increasing interest. The aim of the study was to evaluate two in-house real-time Schistosoma PCRs, targeting respectively S. mansoni [Sm] and S. haematobium [Sh] in excreta, biopsies and sera as potential tools to diagnose active infections and to monitor treatment efficacy. Methods Schistosoma PCRs were performed on 412 samples (124 urine, 86 stools, 8 biopsies, 194 sera) from patients with suspected schistosomiasis, before anti-parasitic treatment. Results were compared to microscopic examination and serological assays (enzyme-linked immunosorbent assay (ELISA), indirect haemagglutination (HA) and Western Blot (WB) assay). Results Compared to microscopy, PCRs significantly increased the sensitivity of diagnosis, from 4% to 10.5% and from 33.7% to 48.8%, for Sh in urine and Sm in stools, respectively. The overall sensitivity of PCR on serum samples was 72.7% and reached 94.1% in patients with positive excreta (microscopy). The specificity of serum PCR was 98.9%. After treatment, serum PCR positivity rates slowly declined from 93.8% at day 30 to 8.3% at day 360, whereas antibody detection remained positive after 1 year. Conclusion Schistosoma PCRs clearly outperform standard microscopy on stools and urine and could be part of reference methods combined with WB-based serology, which remains a gold standard for initial diagnosis. When serological assays are positive and microscopy is negative, serum PCRs provide species information to guide further clinical exploration. Biomarkers such as DNA and antibodies are of limited relevance for early treatment monitoring but serum PCR could be useful when performed at least 1 year after treatment to help confirm a cured infection., Author summary Schistosomiasis is one of the most important human parasitic neglected tropical diseases. It is a major source of morbidity and mortality in Africa but also in South America, the Caribbean, the Middle East, and Asia. It is transmitted by skin penetration of schistosome cercariae via contact with freshwater. Schistosoma mansoni and S. haematobium are the most common species and are frequent causes of infection in travelers and migrants returning from endemic areas. Chronic infections with these two species can cause irreversible damage to the liver or genitourinary tract. Diagnosis mainly relies on serological screening and microscopic procedures from urine and stool specimens that can, however, fail to detect low parasite burden and depend on operator competence. So there is a need to improve the detection of this disease. With this retrospective study, we evaluate the accuracy of a specific Schistosoma PCR assay for the diagnosis of schistosomiasis on a large cohort of migrants and travelers returning from endemic areas. Our study showed that PCR, a technique allowing Schistosoma DNA amplification and detection, greatly improved the diagnosis of both parasite species in urine, feces and biopsies. We also demonstrate that the detection of circulating Schistosoma DNA in blood by PCR is useful to confirm schistosomiasis diagnosis, to provide a species identification when the microscopy research is negative and to monitor the treatment efficacy.
- Published
- 2019
29. Giant coronary artery aneurysm in a patient with LEOPARD syndrome
- Author
-
Xavier Iriart, Jean-Benoit Thambo, Marion Bourgain, and Hubert Cochet
- Subjects
Multiple lentigines syndrome ,Coronary artery aneurysm ,medicine.medical_specialty ,Images in Cardiology ,business.industry ,Internal medicine ,medicine ,Cardiology ,Cardiology and Cardiovascular Medicine ,business ,medicine.disease ,LEOPARD Syndrome - Published
- 2019
30. Heart rate response during exercise predicts exercise tolerance in adults with transposition of the great arteries and atrial switch operation
- Author
-
Jérémy Jaussaud, Jean-Benoit Thambo, Hervé Douard, Xavier Iriart, Soazig Le Quellenec, Xavier Pillois, Hubert Cochet, Zakaria Jalal, François Roubertie, and Institut de rythmologie et modélisation cardiaque [Pessac] (IHU Liryc)
- Subjects
Adult ,Male ,Cardiac output ,medicine.medical_specialty ,[SDV]Life Sciences [q-bio] ,Transposition of Great Vessels ,Magnetic Resonance Imaging, Cine ,030204 cardiovascular system & hematology ,Transposition (music) ,03 medical and health sciences ,0302 clinical medicine ,Cardiac magnetic resonance imaging ,Heart Rate ,Predictive Value of Tests ,Internal medicine ,Hyperventilation ,medicine ,Humans ,030212 general & internal medicine ,Cardiac imaging ,Retrospective Studies ,Exercise Tolerance ,medicine.diagnostic_test ,business.industry ,VO2 max ,Arterial Switch Operation ,medicine.anatomical_structure ,Ventricle ,Great arteries ,Cardiology ,Exercise Test ,Female ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business - Abstract
To assess the relationship between heart rate response and exercise tolerance in adults with systemic right ventricle (sRV) after atrial switch repair for Transposition of the Great Artery (TGA) in addition to other physiological parameters.All patients with a sRV after atrial switch repair for TGA followed in our institution between June 2015 and April 2018 who underwent cardiopulmonary exercise testing (CPET) were analyzed. Cardiac imaging performed within a six-month time period of the CPET were also collected. Chronotropic incompetence was defined as the inability to achieve 80% of age-predicted maximal heart rate reserve (HRR) and62% on a beta-blocker regimen. Patient characteristics were assessed according to tertiles of the percentage of predicted pVO2 (%ppVO2).We studied 70 patients (mean of age 32.4 ± 7.6 years old, 51 males). Mean peak oxygen uptake was 21.5 ± 5.8 mL/kg/min, corresponding to a %ppVO2 of 57 ± 14.1% while mean VE/VCO2 slope was 37.1 ± 8.2. There was a trend toward more exaggerated hyperventilation in patient with lower pVO2. Mean age-adjusted HRR was 68.5 ± 19%. Chronotropic incompetence was observed in 65.7% and was correlated with %ppVO2 (r = 0.482; p 0.001) as physical training evaluated with Ventilatory Anaerobic threshold (r = 0.571; p 0.001), while no difference was found based on respiratory parameters. No echocardiographic or Magnetic Resonance Imaging parameters assessing sRV systolic function at rest were correlated with %ppVO2.Exercise limitation is related to the inability to increase cardiac output during exercise and is notably due to the degree of chronotropic incompetence.
- Published
- 2019
31. Factors associated with exercise capacity in patients with a systemic right ventricle
- Author
-
Magalie Ladouceur, Marie-Christine Picot, Xavier Iriart, Matthieu Rola, Chris Serrand, Charlene Bredy, Pascal Amedro, Arthur Gavotto, Jean-Benoit Thambo, Laurence Iserin, Hamouda Abassi, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Aix Marseille Université (AMU), Hôpital de la Colombière, Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), MORNET, Dominique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), and Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Adult ,Male ,medicine.medical_specialty ,Multivariate analysis ,[SDV.MHEP.PHY] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO] ,Heart Ventricles ,Ventricular Dysfunction, Right ,030204 cardiovascular system & hematology ,Implantable defibrillator ,03 medical and health sciences ,Oxygen Consumption ,0302 clinical medicine ,Deconditioning ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Cardiac magnetic resonance imaging ,Risk Factors ,Internal medicine ,Heart rate ,medicine ,[SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO] ,Humans ,030212 general & internal medicine ,Cardiopulmonary exercise test ,NYHA functional class ,Congenital heart disease ,Univariate analysis ,Exercise Tolerance ,medicine.diagnostic_test ,business.industry ,Systemic right ventricle ,VO2 max ,Middle Aged ,[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Cross-Sectional Studies ,medicine.anatomical_structure ,Ventricle ,Exercise Test ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business ,Anaerobic exercise ,human activities - Abstract
International audience; Background: Systemic right ventricle (RV) is a rare and complex congenital heart disease (CHD). Patients with a systemic RV present with a significant decrease of their exercise capacity. We aimed at identifying clinical and paraclinical factors associated with maximum oxygen uptake (VO2max) in adults with a systemic RV.Methods: This multicentre cross-sectional study was performed in 2017 in three French tertiary care CHD centres. Adult patients with a D-transposition of the great artery (d-TGA) or a congenitally corrected TGA (cc-TGA) were included. Demographic, clinical, laboratory and imaging data were collected. Univariate and multivariate analyses were performed to identify predictors of impaired VO2max, as measured by cardiopulmonary exercise test (CPET).Results: A total of 111 patients were included in the study (85% d-TGA, median age 37.2 ± 8.2 years). Most patients presented with impaired physical capacity (mean VO2max of 23.3 ± 6.9 ml/kg/min, representing 68.4 ± 16.6% of predicted values) and ventilatory anaerobic threshold (VAT) impaired (mean VAT of 32.7 ± 10.9% of the predicted values). In univariate analysis, VO2max correlated with professional status, NYHA functional class, BNP level, the type of systemic RV, decreased RV function values in cardiac imaging, the severity of tricuspid regurgitation, the presence of a pacemaker or an implantable defibrillator, the VAT, the maximum load, and the maximal heart rate during exercise. In multivariate analysis, the VO2max remained associated with the NYHA functional class. The final multivariate model explained 49% of the variability of VO2max.Conclusion: NYHA functional class and RV function are predictors of impaired exercise capacity in adult patients with systemic RV.
- Published
- 2019
32. Right ventricular remodelling in CHD-PAH patients using 3D speckle tracking
- Author
-
N Dursent, Emile Ferrari, Nicolas Duchateau, Xavier Iriart, Sébastien Hascoët, Pamela Moceri, Delphine Baudouy, Maxime Sermesant, Centre Hospitalier Universitaire de Nice (CHU Nice), Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Imagerie et modélisation Vasculaires, Thoraciques et Cérébrales (MOTIVATE), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), CHU Bordeaux [Bordeaux], Centre Chirurgical Marie Lannelongue (CCML), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), E-Patient : Images, données & mOdèles pour la médeciNe numériquE (EPIONE), Inria Sophia Antipolis - Méditerranée (CRISAM), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria), Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Centre chirurgical Marie Lannelongue, Hôpital Pasteur [Nice] (CHU), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), and Modeling & analysis for medical imaging and Diagnosis (MYRIAD)
- Subjects
medicine.medical_specialty ,Heart disease ,Age differences ,Ventricular function ,business.industry ,030204 cardiovascular system & hematology ,Age and sex ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Eisenmenger syndrome ,Rv function ,medicine ,Cardiology ,[INFO.INFO-IM]Computer Science [cs]/Medical Imaging ,In patient ,cardiovascular diseases ,030212 general & internal medicine ,Cardiology and Cardiovascular Medicine ,business ,Shunt (electrical) ,ComputingMilieux_MISCELLANEOUS - Abstract
Introduction Survival in pulmonary arterial hypertension (PAH) relates to right ventricular (RV) function. Whereas prognosis differs widely between PAH associated with congenital heart disease (CHD) and other causes of PAH, only little is known about differences in RV function. Purpose We aimed at comparing RV function assessed by 3D-speckle-tracking in patients with CHD-PAH, other PAH aetiologies and healthy controls; and assess the relationship between ventricular function and prognostic parameters. Methods We performed a prospective multi-centric study between June 2015 and June 2017 recruiting 27 patients with CHD-PAH (3 had closed shunts, 24 had Eisenmenger syndrome; among these, 11 had a pre-tricuspid shunt, 13 had a post-tricuspid shunt), to compare with 27 group 1 non-CHD related-PAH patients (nPAH) and 27 controls matched on age and sex with the CHD-PAH group. Patients with complex CHD were excluded. All patients underwent 2D and 3D transthoracic echocardiography at baseline. 3D RV echocardiographic sequences were analysed by a commercial RV-specific software and output meshes were post-processed to extract deformation data. Results There was no significant age difference between the subgroups. In CHD-PAH patients, RV global area and longitudinal strain did not significantly differ as compared to nPAH but RV global circumferential strain was significantly better (P = 0.006). All strain components were impaired as compared to controls (P Fig. 1 ). Conclusion RV remodelling differs between adults with CHD-PAH and PAH from other aetiologies: 3D RV global circumferential strain is better in CHD-PAH patients and associated with survival free from transplant.
- Published
- 2018
33. Late device-related thrombus after left atrial appendage closure: never let your guard down
- Author
-
Alain Coiffic, Xavier Iriart, Alexandre Metras, and Jean-Benoit Thambo
- Subjects
Appendage ,Cardiac Catheterization ,Guard (information security) ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Treatment outcome ,Left auricular appendage ,Thrombosis ,medicine.disease ,Treatment Outcome ,Left atrial ,Internal medicine ,Atrial Fibrillation ,Cardiology ,Humans ,Medicine ,Atrial Appendage ,Thrombus ,Cardiology and Cardiovascular Medicine ,business ,Echocardiography, Transesophageal ,Cardiac catheterization - Published
- 2020
34. Mitral and aortic paravalvular leaks closure: Insights from the prospective international multicenter FFPP cohort study
- Author
-
Mohammed Nejjari, Rémy Pillière, Nicolas Combes, Sébastien Armero, L. Mangin, Grzegorz Smolka, Guillaume Leurent, Xavier Iriart, Fabrice Bauer, Yoan Lavie-Badie, Christian Spaulding, Hélène Bouvaist, B. Gerardin, Nadjib Hammoudi, Eric Brochet, V. Ciobotaru, Adel Aminian, Claire Dauphin, Sébastien Hascoët, and D. Champagnac
- Subjects
Hemolytic anemia ,medicine.medical_specialty ,Blood transfusion ,Ejection fraction ,Percutaneous ,business.industry ,medicine.medical_treatment ,medicine.disease ,Heart failure ,Internal medicine ,cardiovascular system ,Cardiology ,Medicine ,Cardiology and Cardiovascular Medicine ,business ,Complication ,Stroke ,Cohort study - Abstract
Background Percutaneous paravalvular leak closure (PVLc) has emerged as an alternative to surgery. It remains a technically challenging procedure. We aim to compare outcomes after mitral and aortic PVLc. Methods We analyzed data from PVLc procedures performed over the 2 first years of inclusion in the FFPP (Fermeture de Fuite Periprothetique) study, a prospective observational industry-independent cohort study which started in January 2017. Results We analyzed 147 PVLc (99 mitral–48 aortic), performed in 127 patients (1 procedure in 109 patients, 2 in 16 and 3 in 2) included in 22 centers among 3 countries (France, Poland and Belgium). Age (69 ± 10 versus 69 ± 11 yo), left ventricular ejection fraction (56 versus 51%), Euroscore2 (9 versus 7.6) and rate of mechanical valve (56.7% versus 41.7%, P = 0.1) were not significantly different among mitral and aortic groups. All patients had heart failure and/or hemolytic anemia. Hemolysis was more common in mitral PVL (62 versus 43%, P = 0.04). A mean of 1.4 (min 1, max 3) and 1.8 (min 1 max 5) devices were respectively required for technically successful aortic and mitral PVLc. No complication was reported in procedures with failure of device implantation. Aortic PVLc were faster than mitral PVLc (1h18 versus 2h20), with a trend towards a higher rate of technical success (96% versus 87%, P = 0.1) and fewer rate of major adverse events (worsening hemolysis, stroke, life threatening events and deaths; 2% versus 14%, P = 0.02). At 1 month follow-up, events were reported in 2% of patients (blood transfusion for hemolysis) versus 26.2% (deaths 3.3%; hemolysis 14.8%; heart failure 3.3%; heart failure and hemolysis 4.9%) after successful aortic and mitral PVLc respectively, P = 0.6. Conclusion Mitral PVLc is a more complex procedure than aortic PVLc, with a lower success rate and a higher risk of peri-procedural and one-month severe adverse events. Longer follow-up data are expected and will be available from this on-going study.
- Published
- 2020
35. Human toxocariasis and atopy
- Author
-
Xavier Iriart, Alexis Valentin, Sophie Cassaing, Jean-François Magnaval, Judith Fillaux, Antoine Berry, Laboratoire d'Anthropobiologie (LA), École des hautes études en sciences sociales (EHESS)-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Institut de Chimie du CNRS (INC)-Institut de Recherche pour le Développement (IRD), Service de Parasitologie et Mycologie, CHU Toulouse [Toulouse]-Institut Fédératif de Biologie (IFB) - Hôpital Purpan, Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Université Fédérale Toulouse Midi-Pyrénées, CHU Bordeaux [Bordeaux], Université de Toulouse (UT), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Service de Parasitologie et Mycologie [CHU Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre de Physiopathologie Toulouse Purpan (CPTP), and Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
MESH: Toxocara ,Hypersensitivity, Immediate ,Male ,[SDV]Life Sciences [q-bio] ,MESH: Hypersensitivity, Immediate / parasitology ,Disease ,Immunoglobulin E ,Atopy ,Leukocyte Count ,0302 clinical medicine ,MESH: Eosinophil Cationic Protein / blood ,Clinical picture ,Outpatients ,Eosinophilia ,Outpatient clinic ,MESH: Animals ,Outcome ,0303 health sciences ,MESH: Middle Aged ,biology ,MESH: Immunoglobulin E / blood ,Middle Aged ,3. Good health ,Infectious Diseases ,Female ,France ,IgE ,medicine.symptom ,Research Article ,Adult ,medicine.medical_specialty ,Veterinary (miscellaneous) ,Antibodies, Helminth ,MESH: Eosinophils / cytology ,MESH: Antibodies, Helminth / blood ,lcsh:Infectious and parasitic diseases ,MESH: Hypersensitivity, Immediate / immunology ,03 medical and health sciences ,MESH: Toxocariasis / immunology ,Internal medicine ,medicine ,Animals ,Humans ,lcsh:RC109-216 ,Retrospective Studies ,Toxocara ,030304 developmental biology ,MESH: Humans ,Toxocariasis ,Eosinophil Cationic Protein ,MESH: Adult ,MESH: Retrospective Studies ,Retrospective cohort study ,medicine.disease ,MESH: Male ,MESH: Outpatients ,MESH: France ,Eosinophils ,030228 respiratory system ,Parasitology ,MESH: Leukocyte Count ,Insect Science ,biology.protein ,Animal Science and Zoology ,MESH: Female ,Human toxocariasis - Abstract
To assess the possible influence of atopy on the clinical picture of human toxocariasis, a retrospective study was carried out using file records for patients who attended the Outpatient Clinic of Parasitology in Toulouse University Hospitals. A total of 106 file records for patients who had been diagnosed with common/covert toxocariasis were extracted from the database. Forty-nine patients (20 females and 29 males) were considered atopic since they exhibited a long (≥ 1 year) history of various allergic issues along with a titer ≥ 0.7 kIU/L for specific IgE against at least two out of nine mixes of common inhalant allergens. Fifty-seven patients (42 females and 15 males) were designated nonatopic on the basis of a negative result (0.35 kIU/L) of the test for specific IgE. Demographic (age and sex), clinical (20 signs or symptoms) and laboratory (blood eosinophil count, eosinophil cationic protein, serum total IgE, and specific anti-Toxocara IgE) variables were investigated by bivariate analysis followed by multivariate regression analysis using "atopy" as the outcome variable. On the basis of our results, the clinical or laboratory picture of toxocaral disease was not affected by the presence of an atopic status.Toxocarose humaine et atopie.Pour évaluer la possible influence de l’atopie sur la présentation clinico-biologique de la toxocarose humaine, une étude rétrospective a été réalisée à partir des dossiers de patients vus à la Consultation du Service de Parasitologie-Mycologie du CHU de Toulouse. Cent-six dossiers de patients diagnostiqués comme ayant la forme commune de la toxocarose ont été extraits de la base de données. Quarante-neuf patients (20 femmes et 29 hommes) ont été considérés comme atopiques, eu égard à une longue (≥ 1 an) histoire de manifestations allergiques couplée à une recherche positive (≥ 0.7 kUI/L) des IgE spécifiques contre au moins deux parmi 9 mélanges de pneumallergènes communs. Cinquante-sept patients (42 femmes et 15 hommes) ont été classés non atopiques sur la base d’un résultat négatif ( 0.35 kUI/L) de la recherche d’IgE spécifiques. Les variables démographiques (âge et sexe), cliniques (20 signes ou symptômes) et biologiques (numération des éosinophiles sanguins, dosage des protéines cationiques des éosinophiles, des IgE totales et des IgE spécifiques anti-Toxocara) ont été l’objet d’une analyse statistique bivariée suivie par une régression logistique multivariée, en utilisant “atopie” comme variable à expliquer. Selon nos résultats, le tableau clinique et biologique de la toxocarose n’est pas modifié par la présence d’un état atopique.
- Published
- 2020
36. Role of animal models for percutaneous atrial septal defect closure
- Author
-
Alban-Elouen Baruteau, Zakaria Jalal, Olivier Villemain, David Benoist, Xavier Iriart, Pierre-Emmanuel Séguéla, Jean-Benoit Thambo, Olivier Bernus, and Younes Boudjemline
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Percutaneous ,medicine.diagnostic_test ,business.industry ,Volume overload ,Magnetic resonance imaging ,Atrial septal defect closure ,Review Article ,030204 cardiovascular system & hematology ,medicine.disease ,Thrombosis ,Intracardiac injection ,03 medical and health sciences ,0302 clinical medicine ,Infective endocarditis ,Internal medicine ,Cardiology ,Medicine ,030212 general & internal medicine ,business ,Large animal - Abstract
As for any preclinical development of new implantable device, bench testing has been followed by experimental studies on large animal models for the development of atrial septal defect closure devices. Various models have been used according to studied species (porcine, ovine or canine model) and whether the septal defect was percutaneously or surgically created. Animal models of percutaneous atrial septal defect closure aim to assess the healing process and device endothelialisation, as well as the development of magnetic resonance imaging guided procedures, the short-term effects of volume overload on right ventricular contractility through haemodynamic studies and the understanding of other complications such as nickel hypersensitivity. Each technique has its own advantages and drawbacks, and leads to different punch-related, acute septal injuries that could have an effect on the healing process after device implantation. It has been suggested that some long-term, major device-related complications such as thrombosis or infective endocarditis may be associated with an inappropriate healing process or insufficient endothelialisation of the device, leading industrial companies to pay a great deal of attention to the healing process. Tissue reactions in animal models were shown to adequately reproduce the healing response after device implantation in humans, with an endothelial device coverage observed as early as 30 days after implantation and complete after 3 to 6 months. Research perspectives may evaluate both animal models and in-vitro studies in parallel with a view to clarify the endothelialisation process using human endothelial cells through in-vitro experiments. Self-sensing device for detecting the presence of endothelial cells on the surface of intracardiac occluders and high-resolution imaging techniques that could non-invasively assess the complete endothelialisation of a device would also be promising tools which would need large animal models studies before their clinical application.
- Published
- 2018
37. Percutaneous Left Atrial Appendage Closure Is a Reasonable Option for Patients With Atrial Fibrillation at High Risk for Cerebrovascular Events
- Author
-
Emmanuel Teiger, Jean-Benoit Thambo, Pascal Defaye, Jean-Sylvain Hermida, Sélim Abbey, Didier Klug, Jean-Michel Juliard, Jean-Luc Pasquie, Gilles Rioufol, Antoine Lepillier, Meyer Elbaz, Jerome Horvilleur, Philippe Brenot, Bertrand Pierre, Philippe Le Corvoisier, Nicolas Amabile, Marian Andronache, Frederic Anselme, Sebastien Armero, Pierre Aubry, Etienne Audureau, Dominique Babuty, Babe Bakouboula, Clement Bars, Alban-Elouen Baruteau, Jacques Bille, Jean-Louis Bonnet, Francois Brigadeau, Eric Brochet, Sok-Sithikun Bun, Guillaume Cailla, Olivier Cesari, Didier Champagnac, Philippe Chevalier, Nicolas Combes, Bertrand Comet, Philippe Commeau, Jean-Claude Dearo, Antoine Dompnier, Bruno Farah, Philippe Garot, Daniel Gras, Cedric Giraudeau, Mathieu Granier, Patrice Guerin, Xavier Iriart, Zakaria Jalal, Laurence Jesel-Morel, Antoine Jeu, Priscille Kamtchueng, Nicolas Lellouche, Nicolas Meneveau, Norbert Nighoghossian, Akli Otmani, Remy Pelliere, Remy Pillière, Maxime Pons, Batric Popovic, Pénélope Pujadas, Roland Rossi, Antoine Roux, Yannick Saludas, Christian Spaulding, Victor Statiev, Julien Ternacle, Sarah Traulle, Pierre-François Winum, Institut Mondor de recherche biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service cardiologie pédiatrique [Bordeaux], CHU Bordeaux [Bordeaux], Cardiac Stimulation and Rhythmology, CHU Grenoble, CHU Amiens-Picardie, Hôpital cardiologique, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Bichat - Claude Bernard, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital Cardiovasculaire Louis Pradel, Hospices Civils de Lyon (HCL), Service de cardiologie [Toulouse], Hôpital de Rangueil, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Griset SA, Diehl - Griset, and CIC - CHU Henri Mondor
- Subjects
Male ,medicine.medical_specialty ,Cardiac Catheterization ,anticoagulants ,Percutaneous ,Time Factors ,Septal Occluder Device ,[SDV]Life Sciences [q-bio] ,Population ,Clinical Decision-Making ,Atrial Appendage ,Comorbidity ,030204 cardiovascular system & hematology ,Prosthesis Design ,Risk Assessment ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,medicine ,Humans ,atrial fibrillation ,030212 general & internal medicine ,Prospective Studies ,cardiovascular diseases ,education ,Stroke ,Aged ,education.field_of_study ,cerebral hemorrhage ,Interventional cardiology ,business.industry ,Incidence ,atrial appendage ,Atrial fibrillation ,medicine.disease ,stroke ,3. Good health ,Clinical trial ,Cerebrovascular Disorders ,Treatment Outcome ,Cardiology ,Female ,France ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background— Percutaneous left atrial appendage (LAA) closure is an emerging option for patients with atrial fibrillation at high risk for cerebrovascular events. The multicenter FLAAC registry (French Nationwide Observational LAA Closure Registry) was established to assess LAA closure outcomes in everyday practice. Methods and Results— Four hundred thirty-six patients referred from April 2013 to September 2015 to 33 French interventional cardiology centers for percutaneous LAA closure were included prospectively in the FLAAC registry. Mean age was 75.4±0.4 years. The stroke risk was high (mean CHA 2 DS 2 –VASc score, 4.5±0.1) and most patients had experienced clinically significant bleeding (HAS-BLED score, 3.1±0.05). The device used was Amplatzer LAA occluder in 58% and the Watchman device in 42% of the patients. The procedural success rate was 98.4%. Median postprocedure follow-up was 12.0 (11.8–12.0) months and a single patient was lost to follow-up. During the periprocedural and subsequent follow-up period, procedure-related severe adverse events occurred in 21 (4.9%) and 10 (2.3%) patients, respectively. One-year cumulative incidences of ischemic stroke and cerebral hemorrhage were 2.9% (1.6–5.0) and 1.5% (0.7–3.2), respectively. Overall, 1-year mortality was 9.3% (6.9–12.5) with 7 of the 39 deaths related or possibly related to the device or procedure. Conclusions— This nationwide prospective registry shows that, in the French population, LAA closure is mainly used in patients with high comorbidity rates and a poor prognosis. LAA closure in such patients seems reasonable to decrease the stroke rate. The overall health status of these patients should be taken into account during the preprocedural evaluation process. Clinical Trial Registration— URL: https://www.clinicaltrials.gov . Unique identifier: NCT02252861.
- Published
- 2018
38. Left atrial appendage patency and device-related thrombus after percutaneous left atrial appendage occlusion: A computed tomography study
- Author
-
Xavier Iriart, Pauline Renou, Soumaya Sridi, Michel Montaudon, Zakaria Jalal, Olivier Corneloup, Jean-Benoit Thambo, Hubert Cochet, Claudia Camaioni, François Laurent, and Wieme Selmi
- Subjects
Male ,medicine.medical_specialty ,Leak ,Cardiac Catheterization ,Percutaneous ,Septal Occluder Device ,medicine.medical_treatment ,Anastomotic Leak ,030204 cardiovascular system & hematology ,Left atrial appendage occlusion ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Occlusion ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Atrial Appendage ,030212 general & internal medicine ,Thrombus ,Stroke ,Aged ,Retrospective Studies ,Aged, 80 and over ,Ejection fraction ,business.industry ,General Medicine ,medicine.disease ,Thrombosis ,3. Good health ,Prosthesis Failure ,Treatment Outcome ,Echocardiography ,Ischemic Attack, Transient ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business ,Tomography, X-Ray Computed ,Follow-Up Studies - Abstract
Aims Transoesophageal echocardiography studies have reported frequent peri-device leaks and device-related thrombi (DRT) after percutaneous left atrial appendage (LAA) occlusion. We assessed the prevalence, characteristics and correlates of leaks and DRT on cardiac computed tomography (CT) after LAA occlusion. Methods and results Consecutive patients underwent cardiac CT before LAA occlusion to assess left atrial (LA) volume, LAA shape, and landing zone diameter. Follow-up CT was performed after >3 months to assess device implantation criteria, device leaks and DRT. CT findings were related to patient and device characteristics, as well as to outcome during follow-up. One-hundred and seventeen patients (age 74 ± 9, 37% women, CHA2DS2VASc 4.4 ± 1.3, and HASBLED 3.5 ± 1.0) were implanted with Amplatzer cardiac plug (ACP)/Amulet (71%) or Watchman (29%). LAA patency was detected in 44% on arterial phase CT images and 69% on venous phase images. The most common leak location was postero-inferior. LAA patency related to LA dilatation, left ventricular ejection fraction impairment, non-chicken wing LAA shape, large landing zone diameter, incomplete device lobe thrombosis, and disc/lobe misalignment in patients with ACP/Amulet. DRT were detected in 19 (16%), most being laminated and of antero-superior location. DRT did not relate to clinical or imaging characteristics nor to implantation criteria, but to total thrombosis of device lobe. Over a mean 13 months follow-up, stroke/transient ischaemic attack occurred in eight patients, unrelated to DRT or LAA patency. Conclusion LAA patency on CT is common after LAA occlusion, particularly on venous phase images. Leaks relate to LA/LAA size at baseline, and device malposition and incomplete thrombosis at follow-up. DRT is also quite common but poorly predicted by patient and device-related factors.
- Published
- 2018
- Full Text
- View/download PDF
39. Pneumocystis Pneumonia in Solid-Organ Transplant Recipients
- Author
-
Nassim Kamar, Xavier Iriart, Antoine Berry, and Marine Le Bouar
- Subjects
solid-organ transplant recipients ,Microbiology (medical) ,medicine.medical_specialty ,Aids patients ,biology ,business.industry ,Incidence (epidemiology) ,Review ,Plant Science ,Pneumocystis pneumonia ,medicine.disease ,biology.organism_classification ,Transplantation ,Internal medicine ,Epidemiology ,medicine ,Pneumocystis jirovecii ,In patient ,business ,Intensive care medicine ,Solid organ transplantation ,Ecology, Evolution, Behavior and Systematics ,transplantation - Abstract
Pneumocystis pneumonia (PCP) is well known and described in AIDS patients. Due to the increasing use of cytotoxic and immunosuppressive therapies, the incidence of this infection has dramatically increased in the last years in patients with other predisposing immunodeficiencies and remains an important cause of morbidity and mortality in solid-organ transplant (SOT) recipients. PCP in HIV-negative patients, such as SOT patients, harbors some specificity compared to AIDS patients, which could change the medical management of these patients. This article summarizes the current knowledge on the epidemiology, risk factors, clinical manifestations, diagnoses, prevention, and treatment of Pneumocystis pneumonia in solid-organ transplant recipients, with a particular focus on the changes caused by the use of post-transplantation prophylaxis.
- Published
- 2015
40. Liver stiffness measurements for evaluation of central venous pressure in congenital heart diseases
- Author
-
Jean-Baptiste Hiriart, Xavier Iriart, Jean-Benoit Thambo, Zakaria Jalal, Victor de Lédinghen, Juliette Foucher, J. Vergniol, and Thomas Barnetche
- Subjects
Adult ,Heart Defects, Congenital ,Liver Cirrhosis ,Male ,Cardiac Catheterization ,medicine.medical_specialty ,Central Venous Pressure ,Heart disease ,Statistics as Topic ,Population ,Chronic liver disease ,Internal medicine ,Ascites ,medicine ,Humans ,Child ,education ,education.field_of_study ,business.industry ,Area under the curve ,Central venous pressure ,Reproducibility of Results ,Middle Aged ,medicine.disease ,Surgery ,Liver ,Child, Preschool ,Heart failure ,Cardiology ,Elasticity Imaging Techniques ,Female ,France ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Transient elastography - Abstract
Transient elastography (TE; Fibroscan, Echosens, France) is a non-invasive and reproducible approach to assess liver stiffness (LS). LS has been reported to be associated with fibrosis but central venous pressure (CVP) can also influence LS values. We sought to evaluate the correlation between LS and CVP in a large cohort of children and adults with congenital heart disease.All patients referred in our institution between 2012 and 2013 for diagnostic or interventional right heart catheterisation (RHC) were prospectively enrolled excluding patients with acute heart failure, chronic alcohol abuse, chronic liver disease, severe obesity and ascites. Patients underwent LS measurement and CVP measurement by RHC under general anaesthesia within the same or subsequent day.Sixty children (7.4±5.5 years) and 36 adults (38±16 years) were included. Median CVP was 6 mm Hg (range 3-15), median LS was 5 kPa (range 2.8-47.2). LS significantly correlated with CVP (r=0.75, p10(-4)). In the two subgroups (ie, children and adults), correlation was r=0.68 and r=0.84 (p10(-4)), respectively. In the overall population, the area under the curve of LS for identification of CVP10 mm Hg was 0.972 (95% CI 0.855 to 1; p0.05). Optimal cut-off value of LS for detection of CVP10 mm Hg was 8.8 kPa (sensitivity=91.67%, specificity=96.25%).LS measurement using TE is a rapid and reliable method to evaluate CVP in patients with congenital heart disease.
- Published
- 2015
41. Single-centred experience with levosimendan in paediatric decompensated dilated cardiomyopathy
- Author
-
Géraldine Poncelet, Pierre-Emmanuel Séguéla, Xavier Iriart, Karine Nubret, Jana Assy, Jean-Benoit Thambo, Jean-Baptiste Mouton, Nadir Tafer, and Philippe Mauriat
- Subjects
Inotrope ,Male ,Levosimendan ,medicine.medical_treatment ,Nipecotic Acids ,Dilated cardiomyopathy ,Hemodynamics ,Piperazines ,Paediatric heart failure ,Ultrasonography ,Heart transplantation ,Ejection fraction ,General Medicine ,Insuffisance cardiaque pédiatrique ,Carbocyanines ,Brain natriurétique peptide ,Brain natriuretic peptide ,Paediatric heart transplantation ,Pyridazines ,Treatment Outcome ,Child, Preschool ,Creatinine ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,medicine.drug ,Cardiomyopathy, Dilated ,medicine.medical_specialty ,Cardiotonic Agents ,Adolescent ,Waiting Lists ,Internal medicine ,medicine ,Humans ,Transplantation cardiaque pédiatrique ,Simendan ,Retrospective Studies ,Heart Failure ,business.industry ,Hydrazones ,Infant ,Stroke Volume ,medicine.disease ,Heart failure ,Drug Evaluation ,Heart Transplantation ,Cardiomyopathie dilatée ,Heart-Assist Devices ,business ,Biomarkers - Abstract
Summary Background Children with dilated cardiomyopathy in advanced heart failure may spend a long time awaiting heart transplantation. Consequently, mechanical circulatory support is sometimes required as a bridge to transplantation. Levosimendan, a positive inotropic agent, has been reported to be safe and efficient for the treatment of paediatric heart failure. Aims To report our experience with levosimendan in children with decompensated dilated cardiomyopathy. Methods Paediatric patients with dilated cardiomyopathy on the transplant waiting list and with criteria for mechanical support were included in this single-centred retrospective study. Each patient received at least one 24-hour infusion of levosimendan before mechanical circulatory support was considered. Biological and echocardiographic data were analysed. Results Six patients were included over a 24-month period. The median age was 25.5 months (7.7–34.2 months); 82 infusions were performed. Median B-type natriuretic peptide concentration decreased significantly between days 0 and 2 (2443 ng/L [1458–3819 ng/L] vs 1358 ng/L [1025–2534 ng/L]; P = 0.003). While only a trend was noted in left ventricular ejection fraction improvement ( P = 0.054 by Simpson's method and P = 0.068 by the Teicholz method), the subaortic velocity time integral rose significantly between days 0 and 8 (12.8 cm/s [10–14.5 cm/s] vs 15.3 cm/s [14.3–16.9 cm/s]; P = 0.041). Conclusions Levosimendan seems to improve haemodynamics in children with decompensated dilated cardiomyopathy; repeated infusions may delay the need for mechanical circulatory support while awaiting heart transplantation. This therapeutic agent should be systematically considered in this setting, in addition to conventional inotropic drugs.
- Published
- 2015
- Full Text
- View/download PDF
42. Risk Factors of Pneumocystis Pneumonia in Solid Organ Recipients in the Era of the Common Use of Posttransplantation Prophylaxis
- Author
-
Laurence Lavayssière, O. Roques, Jean-François Magnaval, Sandie Menard, Lionel Rostaing, A. Del Bello, Sophie Cassaing, Olivier Cointault, Antoine Berry, Judith Fillaux, Rose-Anne Lavergne, Isabelle Cardeau-Desangles, Pamela Chauvin, Nassim Kamar, Xavier Iriart, L. Esposito, T. Challan Belval, CHU Toulouse [Toulouse], Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), and Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Graft Rejection ,Male ,Antifungal Agents ,[SDV]Life Sciences [q-bio] ,Cytomegalovirus ,Pneumocystis carinii ,Pneumocystis pneumonia ,Clinical research ,Postoperative Complications ,Risk Factors ,Immunology and Allergy ,Pharmacology (medical) ,Univariate analysis ,risk stratification ,Pneumonia, Pneumocystis ,Graft Survival ,risk assessment ,Middle Aged ,complication: infectious ,practice ,Tissue Donors ,3. Good health ,fungal ,Cytomegalovirus Infections ,Female ,Risk assessment ,infection and infectious agents ,medicine.medical_specialty ,infectious disease ,lung ,disease: infectious ,Immunocompromised Host ,Internal medicine ,Trimethoprim, Sulfamethoxazole Drug Combination ,medicine ,Humans ,Retrospective Studies ,Transplantation ,business.industry ,Organ Transplantation ,Odds ratio ,Antibiotic Prophylaxis ,medicine.disease ,Transplant Recipients ,Tacrolimus ,Confidence interval ,Surgery ,Case-Control Studies ,business ,Follow-Up Studies - Abstract
International audience; Pneumocystis pneumonia (PCP) in solid organ transplant (SOT) recipients becomes rare in the immediate posttransplantation period thanks to generalized prophylaxis. We aimed to identify the predictive factors for PCP in the era of universal prophylaxis and to propose a strategy for preventing PCP beyond the first year after transplantation. In a retrospective case-control study, 33 SOT cases with PCP diagnosed between 2004 and 2010 were matched with two controls each to identify risk factors for PCP by uni- and multivariate analysis. All the patients benefited from 6 months of posttransplantation trimethoprim-sulfamethoxazole prophylaxis. Most PCP in SOT patients occurred during the second year posttransplantation (33%). By univariate analysis, age, nonuse of tacrolimus, total and CD4 lymphocyte counts, gamma-globulin concentration and cytomegalovirus (CMV) infection appeared to be PCP risk factors. In the final multivariate analysis, age (adjusted odds ratio [OR] 3.7, 95% confidence interval [CI]: 1.3-10.4), CMV infection (OR: 5.2, 95% CI: 1.8-14.7) and total lymphocyte count (OR: 3.9, 95% CI: 1.4-10.7) were found to be independently associated with PCP. The second year posttransplantation appeared to be the new period of highest risk of PCP. Age, CMV viremia and lymphocytes were the most pertinent predictive criteria to evaluate the risk of PCP in clinical practice.
- Published
- 2015
43. Multivariable assessment of the right ventricle by echocardiography in patients with repaired tetralogy of Fallot undergoing pulmonary valve replacement: A comparative study with magnetic resonance imaging
- Author
-
Xavier Iriart, Philippe Mauriat, Jan Marek, Karim Jamal-Bey, Jean-Benoit Thambo, Jean-Bernard Selly, François Roubertie, and Emmanuelle Guilhon
- Subjects
Male ,Time Factors ,Ventricular Dysfunction, Right ,Tétralogie de Fallot ,Echocardiography, Three-Dimensional ,Pulmonary Valve Replacement ,Remplacement valvulaire pulmonaire ,Échocardiographie ,Tetralogy of Fallot ,Heart Valve Prosthesis Implantation ,Ejection fraction ,medicine.diagnostic_test ,General Medicine ,Treatment Outcome ,medicine.anatomical_structure ,Echocardiography ,Area Under Curve ,Cardiology ,Right ventricle ,Female ,Tricuspid Valve ,Radiology ,Cardiology and Cardiovascular Medicine ,IRM ,Adult ,medicine.medical_specialty ,Adolescent ,Heart Ventricles ,Young Adult ,Magnetic resonance imaging ,Predictive Value of Tests ,Internal medicine ,medicine ,Humans ,In patient ,Cardiac Surgical Procedures ,Pulmonary Valve ,Adult patients ,Ventricule droit ,business.industry ,Stroke Volume ,medicine.disease ,Pulmonary Valve Insufficiency ,ROC Curve ,Ventricle ,Pulmonary valve replacement ,Multivariate Analysis ,Ventricular Function, Right ,Feasibility Studies ,business - Abstract
SummaryBackgroundEvaluation of the right ventricle (RV) using transthoracic echocardiography is challenging in patients with repaired tetralogy of Fallot (rTOF).AimsTo evaluate the accuracy of conventional echocardiographic variables and real-time three-dimensional echocardiography (RT3DE) in assessing right ventricular (RV) volumes and function compared with magnetic resonance imaging (MRI), in adult patients with rTOF and referred for pulmonary valve replacement (PVR).MethodsComplete echocardiography was performed on 26 consecutive patients referred for PVR, before and 1 year after surgery. All variables were compared with MRI.ResultsCorrelations between conventional variables and MRI were absent or poor when assessing RV ejection fraction (RVEF), except for fractional area of change (FAC; r=0.70, P
- Published
- 2015
- Full Text
- View/download PDF
44. Hybrid Melody Valve Implantation in Mitral Position in a Child: Usefulness of a 3-Dimensional Printed Model for Preprocedural Planning
- Author
-
Astrid Quessard, François Roubertie, Jean-Benoit Thambo, Bernard Kreitmann, Pierre-Emmanuel Séguéla, Xavier Iriart, and Zakaria Jalal
- Subjects
Models, Anatomic ,Patient-Specific Modeling ,Reoperation ,medicine.medical_specialty ,Treatment outcome ,Ventricular outflow tract obstruction ,Ventricular Outflow Obstruction ,030204 cardiovascular system & hematology ,Prosthesis Design ,Preoperative care ,03 medical and health sciences ,0302 clinical medicine ,Mitral valve stenosis ,Internal medicine ,Mitral valve ,Preoperative Care ,medicine ,Humans ,Mitral Valve Stenosis ,Heart Valve Prosthesis Implantation ,Atrioventricular valve ,business.industry ,Infant ,medicine.disease ,medicine.anatomical_structure ,Treatment Outcome ,030228 respiratory system ,Heart Valve Prosthesis ,Printing, Three-Dimensional ,cardiovascular system ,Cardiology ,Atrioventricular canal ,Mitral Valve ,Risk Adjustment ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business - Abstract
We present the case of a 4-month-old child with atrioventricular canal associated with severe left atrioventricular valve dysfunction who previously underwent 3 surgical valve reconstructions without significant improvement. A Hybrid Melody valve (Medtronic, Minneapolis, MN) insertion was planned. Because of the low weight, the risk of left ventricular outflow tract obstruction was significant and therefore evaluated preprocedurally using a cardiac computed tomography-derived 3-dimensional printed model. In vitro tests showed good anchorage of the valve without subaortic obstruction and the procedure was then achieved with an excellent clinical result.
- Published
- 2017
45. Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study
- Author
-
Pierre Mauran, Ali Houeijeh, Elise Barre, Clément Karsenty, Hélène Bouvaist, Pamela Moceri, Xavier Iriart, Elie Fadel, Adélaïde Richard, Nathalie Souletie, Emmanuelle Fournier, Lauriane Le Gloan, Magalie Ladouceur, Xavier Jaïs, Yvette Bernard, François Godart, Jelena Radojevic, Jérôme Petit, Laurence Iserin, Damien Bonnet, Gilles Bosser, Sébastien Hascoët, Pascal Amedro, Claire Dauphin, Adeline Basquin, Olivier Sitbon, Marc Humbert, Université Paris-Sud - Paris 11 - Faculté de médecine (UP11 UFR Médecine), Université Paris-Sud - Paris 11 (UP11), Centre de Référence des cardiopathies congénitales (M3C), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-PRES Sorbonne Paris Cité-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris-Saclay, Hôpital Bicêtre, Centre hospitalier universitaire de Nantes (CHU Nantes), Service de médecine interne, hôpital Gabriel-Montpied, CHU Clermont-Ferrand, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Bordeaux [Bordeaux], Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de Cardiologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Toulouse [Toulouse], Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Hôpital Pasteur [Nice] (CHU), CHU Grenoble, Centre Hospitalier Universitaire de Reims (CHU Reims), CHU Rouen, Normandie Université (NU), Service de cardiologie et maladies vasculaires, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], CHU Pontchaillou [Rennes], CHU Necker - Enfants Malades [AP-HP], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre chirurgical Marie Lannelongue, Hypertension arterielle pulmonaire physiopathologie et innovation thérapeutique, Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre chirurgical Marie Lannelongue, Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Service de Médecine Interne [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes], and Centre chirurgical Marie Lannelongue-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
Male ,Pediatrics ,Time Factors ,Kaplan-Meier Estimate ,030204 cardiovascular system & hematology ,Pulmonary arterial hypertension ,Gastroenterology ,Congenital heart diseases ,0302 clinical medicine ,Risk Factors ,Cause of Death ,030212 general & internal medicine ,Longitudinal Studies ,Child ,Cause of death ,Outcome ,Cardiopathies congénitales ,Age Factors ,Hypertension artérielle pulmonaire ,General Medicine ,Middle Aged ,[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences ,Syndrome d’Eisenmenger ,3. Good health ,Treatment Outcome ,Disease Progression ,Female ,France ,Drug therapy ,Cardiology and Cardiovascular Medicine ,Cohort study ,Médicament ,Adult ,medicine.medical_specialty ,Adolescent ,Hypertension, Pulmonary ,Pulmonary Artery ,Lower risk ,Disease-Free Survival ,03 medical and health sciences ,Young Adult ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Internal medicine ,medicine ,Pronostic ,Humans ,Arterial Pressure ,Antihypertensive Agents ,Proportional Hazards Models ,Retrospective Studies ,Chi-Square Distribution ,business.industry ,Eisenmenger syndrome ,Retrospective cohort study ,Eisenmenger Complex ,medicine.disease ,Pulmonary hypertension ,Confidence interval ,Transplantation ,Multivariate Analysis ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business - Abstract
International audience; Background: The relationship between pulmonary arterial hypertension-specific drug therapy (PAH-SDT) and mortality in Eisenmenger syndrome (ES) is controversial.Aims: To investigate outcomes in patients with ES, and their relationship with PAH-SDT.Methods: Retrospective, observational, nationwide, multicentre cohort study.Results: We included 340 patients with ES: genetic syndrome (n = 119; 35.3%); pretricuspid defect (n = 75; 22.1%). Overall, 276 (81.2%) patients received PAH-SDT: monotherapy (endothelin receptor antagonist [ERA] or phosphodiesterase 5 inhibitor [PDE5I]) 46.7%; dual therapy (ERA + PDE5I) 40.9%; triple therapy (ERA + PDE5I + prostanoid) 9.1%. Median PAH-SDT duration was 5.5 years [3.0–9.1 years]. Events (death, lung or heart-lung transplantation) occurred in 95 (27.9%) patients at a median age of 40.5 years [29.4–47.6]. The cumulative occurrence of events was 16.7% [95% confidence interval 12.8–21.6%] and 46.4% [95% confidence interval 38.2–55.4%] at age 40 and 60 years, respectively. With age at evaluation or time since PAH diagnosis as time scales, cumulative occurrence of events was lower in patients taking one or two PAH-SDTs (P = 0.0001 and P = 0.004, respectively), with the largest differences in the post-tricuspid defect subgroup (P < 0.001 and P < 0.02, respectively) versus patients without PAH-SDT. By multivariable Cox analysis, with time since PAH diagnosis as time scale, New York Heart Association/World Health Organization functional class III/IV, lower peripheral arterial oxygen saturation and pretricuspid defect were associated with a higher risk of events (P = 0.002, P = 0.01 and P = 0.04, respectively), and one or two PAH-SDTs with a lower risk of events (P = 0.009).Conclusions: Outcomes are poor in ES, but seem better with PAH-SDT. ES with pretricuspid defects has worse outcomes despite the delayed disease onset.; Contexte: L’intérêt du traitement médical spécifique (TMS) de l’hypertension artérielle pulmonaire (HTAP) dans le syndrome d’Eisenmenger (SE) est controversé.Objectifs: Étudier le pronostic à long terme des patients ayant un SE et la relation avec le TMS.Méthodes: Une cohorte observationnelle longitudinale multicentrique rétrospective historique française de 340 SE a été constituée.Résultats: Le shunt était prétricuspide dans 75 cas (22,1 %). Au total, 276 (81,2 %) patients étaient sous TMS (monothérapie 46,7 % ; bi-thérapie 40,9 % ; tri-thérapie 9,1 %). La durée médiane de TMS était de 5,5 ans [3,0–9,1]. Un événement clinique majeur (ECM : décès, transplantation cardiopulmonaire ou bipulmonaire) a été observé dans 95 (27,9 %) cas à un âge médian de 40,5 [29,4–47,6] ans. La survenue cumulée d’un ECM était de 16,7 % [IC 95 % 12,8–21,6 %] et 46,4 % [IC 95 % 38,2–55,4 %] à l’âge de 40 et 60 ans. Avec l’âge ou le délai depuis le premier examen comme échelle temporelle, la survenue cumulée des ECM était moindre chez les patients sous un ou deux TMS (p = 0,0001 et p = 0,004), en particulier chez les patients avec un shunt post-tricuspide (p < 0,001 et p < 0,02) comparée aux patients sans TMS. Une analyse multivariée de Cox avec le délai depuis le diagnostic de l’HTAP comme échelle temporelle a montré qu’une classe fonctionnelle III ou IV de la NYHA/WHO, une saturation périphérique en oxygène basse (en variable continue), un shunt pré-tricuspide et l’absence de TMS étaient associés à un risque augmenté d’ECM (p = 0,002 ; p = 0,01 ; p = 0,04 and p = 0,009, respectivement).Conclusions: Le TMS dans le SE semble associé à un meilleur pronostic. Néanmoins, même avec un traitement médical palliatif, le pronostic du SE reste altéré. Les patients avec un shunt prétricuspide ont un profil clinique et un pronostic plus sombre malgré une survenue plus tardive de l’HTAP.
- Published
- 2017
46. Focal scar and diffuse myocardial fibrosis in patients with history of repaired Tetralogy of Fallot
- Author
-
Marie-Lou Dinet, Soumaya Sridi, Antoine Allain-Nicolaï, Hubert Nivet, Xavier Iriart, Zakaria Jalal, François Laurent, Emmanuelle Fournier, Jean-Benoit Thambo, Hubert Cochet, Claudia Camaioni, and Michel Montaudon
- Subjects
medicine.medical_specialty ,Ejection fraction ,business.industry ,medicine.disease ,Both ventricles ,Diffuse fibrosis ,Internal medicine ,cardiovascular system ,medicine ,Cardiology ,Myocardial fibrosis ,In patient ,cardiovascular diseases ,Cardiology and Cardiovascular Medicine ,Wall thickness ,business ,Cardiac magnetic resonance ,Tetralogy of Fallot - Abstract
Background Left and right ventricular (LV and RV) remodeling in repaired tetralogy of Fallot (TOF) is poorly understood. Objectives To identify correlates of focal scar and diffuse fibrosis in patients with history of TOF repair by using cardiac magnetic resonance (CMR). Methods Patients with prior TOF repair underwent CMR including cine imaging to assess ventricular volumes and ejection fraction (EF), T1 mapping to assess LV and RV diffuse fibrosis, and high resolution late gadolinium-enhanced (LGE) imaging to quantify scar size. Structural imaging data were related to clinical characteristics and functional imaging markers. In 40 patients, cine and T1 mapping results were compared to age- and sex-matched controls. Results In total, 103 patients were enrolled (age 28 ± 15 years, 36% women), including 36 with prior PV replacement. Compared to controls, TOF patients showed lower LV and RVEF and higher RV volume, RV wall thickness, and native T1 and ECV values on both ventricles. Scar size related to LVEF and RVEF while LV and RV native T1 related to RV dilatation. On multivariable analysis, scar size and LV native T1 were independent correlates of ventricular arrhythmia. Patients with history of PV replacement showed larger scar on RV outflow tract but LV and RV native T1 were shorter ( Fig. 1 ). Conclusions Focal scar and biventricular diffuse fibrosis are detected on CMR after TOF repair. Scar size relates to systolic dysfunction, and diffuse fibrosis to RV dilatation. Both may be implicated in ventricular arrhythmias. The finding of shorter T1 after PV replacement suggests that diffuse fibrosis may reverse with therapy.
- Published
- 2018
47. Transient elsatography, a key tool in the screening of complications in patients with Fontan circulation
- Author
-
V. de Ledinghen, M. Mostefa-Kara, Xavier Iriart, Jean-Benoit Thambo, Jean Baptiste Hiriart, Zakaria Jalal, J. Chabaneix-Thomas, J. Vergnol, J. Foucher, and Pierre-Emmanuel Séguéla
- Subjects
medicine.medical_specialty ,Cirrhosis ,medicine.diagnostic_test ,business.industry ,Physical examination ,medicine.disease ,Work-up ,Congestive hepatopathy ,Internal medicine ,Cardiology ,medicine ,In patient ,Cardiology and Cardiovascular Medicine ,Complication ,Transient elastography ,Lead (electronics) ,business - Abstract
Backgrounds Congestive hepatopathy usually appears and develops slowly after a Fontan operation, often without obvious clinical features, but it may lead to life-threatening complications. Objective We aim to assess the potential usefulness of the liver stiffness (LS) in the longitudinal follow up of Fontan patients. Material and method Patients were prospectively evaluated using clinical examination, laboratory tests, echocardiography and LS using transient elastography (TF). This work up was made annually or in case of clinical complication. Results Forty-six patients (22.1 ± 8,1 years of age and 9.7 ± 6.5 years post-Fontan) were enrolled. Mean time between first and last work up was 3.27 ± 1.9 years. During this period clinical complication occurred in 12/46 (26%) including 6 arrhythmias, 2 cirrhosis, 1 steato-hepatitis, 3 exudative enteropathies and 2 venous-collateral. Mean LS at baseline was 14 ± 7.4 kPa. LS was significantly higher in patient with complications compared to those who were free from any complication (17.2 ± 7.7 vs. 13.8 ± 5.9 kPa, P = 0.019). No significant change in stiffness was also observed with age (P = 0.73), time since Fontan (P = 0.64), presence fenestration (15 ± 6.8 vs. 15.1 ± 6.7 kPa, P = 0.82) or ventricular morphology (15 ± 13.1 vs. 16 ± 14.1 vs. 10.9 ± 11.6 kPa, P = 0.09). Conclusion Fibroscan appears to be a good tool for the non-invasive follow-up of FP. Indeed, a significate elevation of the LS is associated with the occurrence of complications.
- Published
- 2019
48. Aortic Coarctation Diagnosed During Pregnancy in a Woman With Repaired Tetralogy of Fallot
- Author
-
Jean-Benoit Thambo, Xavier Iriart, and Zakaria Jalal
- Subjects
Adult ,Pulmonary and Respiratory Medicine ,Aortic arch ,medicine.medical_specialty ,Pregnancy Complications, Cardiovascular ,Aortic Coarctation ,Postoperative Complications ,Pregnancy ,medicine.artery ,Internal medicine ,Humans ,Medicine ,In patient ,cardiovascular diseases ,Covered stent ,Tetralogy of Fallot ,medicine.diagnostic_test ,business.industry ,Magnetic resonance imaging ,medicine.disease ,Surgery ,Blood pressure ,cardiovascular system ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
Aortic coarctation is thought to be a rare condition in patients with tetralogy of Fallot. We report the case of a 26 year old woman presenting with systemic hypertension at 17 weeks of pregnancy after repair of tetralogy of Fallot in childhood. Echocardiography and magnetic resonance imaging revealed right aortic arch with severe isthmic coarctation. Her blood pressure was controlled medically during the rest of her pregnancy, and delivery was uneventful. Successful transcatheter placement of a covered stent at the level of the coarctation was performed after delivery. To our knowledge, this is the first reported case of aortic coarctation diagnosed in an adult patient late after repair of tetralogy of Fallot.
- Published
- 2015
49. Biventricular pacing in patients with Tetralogy of Fallot: Non-invasive epicardial mapping and clinical impact
- Author
-
Jean-Benoit Thambo, Pierre Dos Santos, Maxime De Guillebon, Louis Labrousse, Xavier Iriart, Michel Haïssaguerre, François Roubertie, Sylvain Ploux, Olivier Xhaet, and Pierre Bordachar
- Subjects
Adult ,Epicardial Mapping ,Male ,medicine.medical_specialty ,Time Factors ,medicine.medical_treatment ,Bundle-Branch Block ,Cardiac resynchronization therapy ,Cardiac Resynchronization Therapy ,Contractility ,Infundibulum ,Internal medicine ,Humans ,Medicine ,Prospective Studies ,cardiovascular diseases ,Prospective cohort study ,Ventricular dyssynchrony ,Tetralogy of Fallot ,business.industry ,Right bundle branch block ,medicine.disease ,medicine.anatomical_structure ,Ventricle ,cardiovascular system ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business ,Follow-Up Studies - Abstract
Introduction: Patients who have undergone repair of Tetralogy of Fallot (TOF) often present with right bundle branch block. Cardiac resynchronization therapy (CRT) with right ventricular (RV) or biventricular (BiV) stimulation has been proposed as a modality to correct electrical abnormalities and improve cardiac contractility in patients with repaired TOF. We aimed to 1) compare ventricular electrical activation in adults with repaired TOF during RV versus BiV stimulation, using a non-invasive epicardial mapping system, and 2) examine the clinical mid-term effects of BiV resynchronization. Methods: 9 adults with repaired TOF were implanted with a CRT system and underwent 1) a non-invasive epicardial mapping (n = 9) during sinus intrinsic rhythm, RV and BiV pacing 2) a clinical evaluation (n = 7) before and after 6 months CRT with assessment of NYHA class and exercise capacity. Results: During intrinsic rhythm, non-invasive mapping demonstrated delayed activation of the right compared with the left ventricle in all patients, with the greatest activation delay noted near the infundibulum. However, we observed important differences among patients, in the severity of activation delays. Global activation time and an index of dyssynchrony were improved (p < 0.05) during BiV pacing compared with RV pacing and spontaneous rhythm. BiV pacing increased (p < 0.05) exercise tolerance and lowered the mean NYHA functional class at 6 months of follow up. Conclusion: Patients with corrected TOF present with different patterns of ventricular activation. RV stimulation modestly improved RV activation sequence and was associated with a delayed LV activation. Biventricular stimulation significantly decreased right and left ventricular dyssynchrony. © 2011 Elsevier Ireland Ltd.
- Published
- 2013
50. Percutaneous left atrial appendage closure followed by single antiplatelet therapy: Short- and mid-term outcomes
- Author
-
Xavier Pillois, Xavier Iriart, Pauline Renou, Zakaria Jalal, Jean-Benoit Thambo, Igor Sibon, Nicolas Combes, and Marie-Lou Dinet
- Subjects
Male ,medicine.medical_specialty ,Cardiac Catheterization ,Ticlopidine ,Time Factors ,medicine.medical_treatment ,Hemorrhage ,030204 cardiovascular system & hematology ,Drug Administration Schedule ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Atrial Fibrillation ,Medicine ,Humans ,Atrial Appendage ,030212 general & internal medicine ,Prospective Studies ,Registries ,Thrombus ,Contraindication ,Stroke ,Cardiac catheterization ,Aged ,Aged, 80 and over ,Aspirin ,business.industry ,Atrial fibrillation ,Thrombosis ,General Medicine ,medicine.disease ,Surgery ,Clopidogrel ,Treatment Outcome ,Cardiology ,Platelet aggregation inhibitor ,Female ,France ,Cardiology and Cardiovascular Medicine ,business ,Tomography, X-Ray Computed ,Platelet Aggregation Inhibitors ,medicine.drug - Abstract
Background After left atrial appendage closure (LAAC), various antithrombotic protocols have been suggested, but the optimal post-procedural antithrombotic strategy is still under debate. Aims To investigate the efficacy and safety of LAAC with an AMPLATZER™ Cardiac Plug (ACP) device (St. Jude Medical, Minneapolis, MN, USA) followed by single antiplatelet therapy. Methods Consecutive patients with non-valvular atrial fibrillation and a contraindication for oral anticoagulants who underwent LAAC with an ACP device between 2012 and 2014 in two French centres were included. Follow-up included clinical evaluation at 1, 3, 6 and 12 months, and yearly thereafter, and a cardiac computed tomography scan at 3 months to assess device position, device-related thrombus and residual leak. Single antiplatelet therapy was prescribed after the procedure for at least 12 months. Results A total of 76 patients underwent successful LAAC (mean age: 73 years; 59% men; mean CHA2DS2-VASc score 4.4 ± 1.3; mean HAS-BLED score 3.4 ± 0.9). Three major complications occurred during the periprocedural period (one cardiac tamponade and two access site haematomas). Device thrombosis was observed at 3 months in five (6.8%) patients who remained asymptomatic. After a mean follow-up of 13 months, the rates of death, stroke and major bleeding were 2.6%, 4.0% and 1.3%, respectively. Embolic and bleeding events were less frequent than expected from CHA2DS2-VASc (4.0% vs 9.9%; P
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.